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 ZUSAMMENFASSUNG  
Immunantworten auf Kuhmilchproteine:  
Molekulare Allergencharakterisierung und Epitop-Mapping 
 
Kuhmilchallergie ist die am häufigsten auftretende Lebensmittelallergie innerhalb der 
ersten Lebensjahre und betrifft ungefähr 2-3% aller Säuglinge und Kleinkinder in 
Industrieländern. Die meisten Patienten mit Kuhmilchallergie leiden unter 
Symptomen, die mehr als ein Organ betreffen, wie zum Beispiel kutane, 
gastrointestinale und respiratorische Symptome und im schlimmsten Fall 
lebensbedrohliche anaphylaktische Reaktionen. Ungefähr 60% aller allergischen 
Reaktionen auf Kuhmilch sind IgE-vermittelt und ungefähr 40% sind nicht-IgE-
vermittelt. Die Mechanismen bei nicht-IgE-vermittelten Unverträglichkeiten sind nicht 
genau bekannt und können andere Immunglobuline und/oder zell-vermittelte 
Wirkungsweisen umfassen.  
Der Schwerpunkt dieser Dissertation liegt in der Isolierung von cDNAs, die für 
Hauptallergene in der Kuhmilch kodieren, sowie in der Expression dieser Allergene in 
rekombinanter Form in Escherichia coli. Dabei wurden zwei Milchproteine, Alpha-
Laktalbumin aus der Molkefraktion und AlphaS1-Kasein aus der Kaseinfraktion im 
Detail charakterisiert. Beide Allergene wurden hinsichtlich ihrer biochemischen 
Eigenschaften mittels SDS-PAGE, Zirkulardichroismus und Massenspektrometrie 
analysiert. Ihre IgE Reaktivität wurde durch Immunblotting und ELISA gezeigt und 
ihre biologische Aktivität durch Degranulation von basophilen Granulozyten bestätigt. 
Durch die Anwendung von synthetischen Peptiden wurden lineare Epitope auf 
beiden Allergenen gefunden und es konnte das Vorhandensein von 
Konformationsepitopen nachgewiesen werden. Diese beiden rekombinanten 
Allergene können nun für eine Komponenten-spezifische Diagnostik bei Patienten 
mit Kuhmilchallergie verwendet werden.  
Weiters wurden die IgE-reaktiven und biologisch aktiven Allergene zur Entwicklung 
eines neuen Diagnosesystems verwendet, das aus einem Allergen-Mikroarray und 
einem Test zur Bestimmung von Mediatorenfreisetzung besteht. Die Mikroarray-
Technologie erlaubt die Austestung von vielen verschiedenen Allergenen auf einmal, 
dies stellt vor allem bei dem Vorhandensein von kleinen Serummengen bei 
Säuglingen und Kleinkindern einen großen Vorteil dar. Die Kombination mit einem 
biologischen Test ermöglicht es, Patienten mit Risiko für starke systemische 
Reaktionen zu identifizieren. Dies ist sinnvoll bei starken Kuhmilchallergikern, die 
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beim Durchführen von in vivo Tests wie Provokationstests an starken Reaktionen 
leiden könnten.  
Ein anderer Scherpunkt dieser Dissertation liegt in der Untersuchung von 
immunologischen Mechanismen, die durch eventuell nicht-IgE-vermittelte Reaktionen 
nach Konsum von Kuhmilch auftreten können. Die Bestimmung von IgG1-4 
Subklassen und IgA Antikörpern gegen gereinigte rekombinante Proteine zeigte, 
dass Patienten mit nicht-IgE-vermittelter Kuhmilchunverträglichkeit basierend auf der 
humoralen Immunantwort auf Kuhmilchantigene nicht von Personen ohne 
Kuhmilchintoleranz unterschieden werden können. Wir sind deshalb zu dem Schluss 
gekommen, dass andere Antikörper als IgE geringen Einfluss auf 
Kuhmilchunverträglichkeiten haben.  
Zusammenfassend war es möglich, innerhalb dieser Dissertation Hilfsmittel zu 
entwickeln, die bei der Komponenten-spezifischen Diagnostik von IgE-vermittelter 
und nicht-IgE-vermittelter Kuhmilchallergie eingesetzt werden können. Dadurch 
erhält man wertvolle Informationen, die in Zukunft bei der Entwicklung von Strategien 
zur Behandlung von Kuhmilchallergie verwendet werden können.  
 
 SUMMARY  
Immune responses to cow’s milk allergens: 
Molecular allergen characterization and epitope mapping 
 
Cow’s milk allergy is the most prevalent food allergy in the first years of life, affecting 
about 2 to 3% of infants and young children in developed countries. Most cow’s milk 
allergic patients suffer from symptoms in more than one organ system showing 
cutaneous, gastrointestinal, respiratory symptoms, and in the worst case 
anaphylactic reactions. Around 60% of all allergic reactions to cow’s milk are IgE-
mediated and around 40% are non-IgE-mediated. The mechanisms of the later might 
involve other immunoglobulins, immune complexes, and/ or cell-mediated 
mechanisms. 
The main aim of this thesis was the isolation of cDNAs coding for major cow’s milk 
allergens and the expression of these allergens in a recombinant form in Escherichia 
coli. The focus was on two milk proteins, alpha-lactalbumin, deriving from the whey 
fraction, and alphaS1-casein, deriving from the casein fraction. Both allergens were 
biochemically characterized using SDS-PAGE, circular dichroism analysis, and mass 
spectrometry. Their IgE reactivity was demonstrated by immunoblotting and ELISA 
and their allergenic activity was proven using rat basophil leukaemia cells transfected 
with the human FcεRI. Using synthetic peptides I could map sequential IgE-epitopes 
on the two allergens and I was able to show in case of both allergens also the 
presence of conformational IgE epitopes. These two recombinant allergens can be 
used for component resolved diagnosis of patients suffering from cow’s milk allergy.  
I further utilized the IgE-reactive and biologically active allergens for the development 
of a novel diagnostic system, consisting of an allergen microarray and a mediator 
release assay. The microarray technology has the advantage that a large panel of 
allergens can be evaluated in parallel especially when only small samples of serum 
are available as for infants and children. The combination with a biological assay 
allows identifying cow’s milk allergic patients that suffer from severe systemic 
reactions. This diagnostic system might therefore represent a useful diagnostic tool 
for highly allergic cow’s milk allergic patients where in vivo tests can not be applied 
because of the risk of allergic reactions. 
Another part of my thesis was focused on the investigation of immunological 
mechanisms involved in non-IgE-mediated cow’s milk allergic reactions. 
Determination of IgG1-4 subclass and IgA antibody levels to purified recombinant 
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allergens showed that based on their humoral immune response to cow’s milk 
antigens, persons suffering from non-IgE-mediated cow’s milk intolerance can not be 
discriminated from persons without cow’s milk intolerance. We therefore concluded 
that antibody-mediated forms of hypersensitivity against cow’s milk allergens, 
besides those mediated by IgE, play no or only a minor role in cow’s milk intolerance. 
In summary, I was able to develop tools for component resolved diagnosis of IgE-
mediated and non-IgE-mediated cow’s milk allergy and to gain information that might 
in the future lead to the design of new strategies for treatment of cow’s milk allergy. 
 
 
 INTRODUCTION 
1. Introduction 
 
1.1. THE HISTORY OF ALLERGY 
One of the earliest reports of allergic disease is that of King Menses of Egypt. He 
was killed by a wasp sting in the year 2641 B.C. (1). It was further reported from 
ancient history, that Britannicus, the son of the Roman Emperor Claudius, was 
allergic to horses and “would develop a rash and his eyes swelled to the extent that 
he could not see where he was going” (2). Lucretius, a Roman philosopher, 
mentioned that some people had adverse reactions to common substances and said, 
“what is food to one may be fierce poison to others”. According to Shakespeare, King 
Richard III suffered from strawberry allergy. In 1565, Leonardo Bottallo gave the first 
modern description of seasonal allergic disorder. 
However, the era of allergy began in the 19th century:  
In 1819 the British physician John Bostock first accurately described hay fever as a 
disease that affected the upper respiratory tract based on his own symptoms (3). In 
1873, Charles Blackley, found the cause of his hay fever by scratching a small 
amount of grass pollen on his skin. This scratching produced a small hive-like 
reaction at the test site, his experiment introduced the concept of the skin test (4). 
Charles Richet and Paul Portier introduced the term anaphylaxis in 1902 (5), when 
life threatening responses to medications and protein substances appeared during 
the course of immunizations. The French immunologist Nicolas Maurice Arthus 
discovered one year later, that repeated injections of horse serum into rabbits 
induced edema, which is nowadays known to be a local vasculitis associated with 
deposition of immune complexes and activation of complement.  
In 1906, the Austrian pediatrician Clemens von Pirquet (Fig. 1) noticed that patients 
had more severe reactions after a second injection of smallpox or horse serum. 
Together with the Hugarian-born physician Bela Schick, he coined the term allergy, 
from the Greek allos meaning “other” and ergon meaning “reaction, work” to describe 
this hypersensitivity reaction (6). Today, allergy is defined as a “hypersensitivity 
reaction initiated by specific immunologic mechanisms” (7). 
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Fig. 1. The term “allergy” was first published in 1906 by 
Clemens von Pirquet in the Münchener Medizinische 
Wochenschrift (8) 
 
The work of Leonard Noon and John Freeman (1911-1914), giving injections of 
small, gradually increasing amounts of allergens to allergic patients, started the 
beginning of modern desensitizing immunotherapy. Prausnitz and Kuestner showed 
in 1921 that an allergic reaction depends on two agents, a serum factor “reagin” and 
a non-specific tissue component. Almost 50 years later, the Japanise couple 
Kimishige and Teruko Ishizaka discovered the role of immunoglobulin E as the most 
important mediator in an allergic reaction (9). At the same time the Swedish group of 
Johannson, Bennich and Wide discovered an atypical myeloma immunoglobulin, 
which was then identified as immunoglobulin E (10). 
Two British immunologists Philip Gell and Robert Coombs classified hypersensitivity 
reactions into four types which is nowadays known as “Gell-Coombs-classification” 
(Fig. 2) (11). 
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1.2. GELL AND COOMBS CLASSIFICATION  
 
 
Fig. 2. Classification of hypersensitivity reactions into four types by Gell and Coombs (12) 
 
1.2.1. TYPE I: IMMEDIATE HYPERSENSITIVITY OR ANAPHYLAXIS 
Type I allergy, also referred as IgE-mediated allergic reaction, affects around 25% of 
the population in industrialized countries (13). Atopy (from the Greek atopos meaning 
“out of place”) was introduced by Arthur Coka and Robert Cooke in 1923 to describe 
the hereditary, familial disposition in a person to produce an allergic response to 
ordinary harmless materials such as pollen, dust, and animal dander and is often 
used in combination with type I allergy. Clinical manifestations of these reactions are 
either local as allergic rhinitis and allergic asthma or systemic as anaphylaxis.  
The reason for the development of an atopic disease is still not completely clear, 
several possibilities are discussed nowadays. Genetic predisposition (14, 15) and 
environmental factors such as air pollution, dietary changes, and exaggerated 
hygiene may play an important role why harmless antigens are wrongly recognized 
and induce IgE production (16-18).  
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The mechanisms of allergic reactions can be summarized in three steps: 
 
1.2.1.1. Sensitization and memory induction 
After small amounts of allergen are deposited on a mucosal surface, the allergen is 
taken up by an antigen-presenting cell (APC) or by an immunoglobulin bound to the 
surface of a B cell. The APC presents a peptide via the MHC to the T-cell receptor of 
a naïve T-cell and this can induce the formation of helper 2 (Th2) cells. The 
differentiation and clonal expansion of Th2 cells go along with the production of 
cytokines such as interleukins IL-4 and IL-13. These interleukins promote the class 
switch of B cells to IgE and the establishment of IgE+memory B-cells (Fig. 3) (19).  
 
1.2.1.2. Immediate phase 
Mast cells and basophils that bind IgE via the high affinity IgE receptor (FcεRI) play a 
major role in the immediate phase. Repeated contact with an allergen leads to a 
cross-linking of FcεRI-bound IgE and then to a degranulation of mast cells and 
basophils. Released histamine, besides other vasoactive amines, lipid mediators, 
chemokines and cytokines can induce immediate symptoms such as tissue swelling, 
itching or in the worst case decrease of blood pressure (Fig. 3). 
 
 
Fig. 3. Sensitization, memory induction and immediate phase of an allergic reaction (19) 
 
1.2.1.3. Late phase: allergic inflammation 
In this phase symptoms appear normally after two or more hours and involve the 
infiltration and activation of Th cells, basophils and eosinophils. These cells release 
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proinflammatory cytokines (e.g. IL-6, IFN-γ, TNF) and cause symptoms like asthma 
or atopic dermatitis (Fig. 4) (19).  
 
 
Fig. 4. Late phase of an allergic reaction (19) 
 
1.2.2. TYPE II: ANTIBODY-MEDIATED CYTOTOXIC REACTIONS  
Type II reactions, also known as cytotoxic reactions, are antibody-mediated. 
Cytotoxic antibodies, mainly IgM or IgG, that bind to the surface of target cells, can 
induce cell damage due to different mechanisms. In the course of an antibody-
dependent cell cytotoxicity reaction (ADCC), immunoglobulin-coated target cells 
attract destructive effector cells (macrophages, neutrophils, eosinophils). In another 
mechanism the classical pathway of the complement systems gets activated through 
bound-antibodies, resulting in cell lysis (11).  
 
1.2.3. TYPE III: IMMUNE COMPLEX-MEDIATED REACTIONS 
In this type of hypersensitivity soluble antigens react with precipitating antibodies in 
the tissue and form immune complexes in and around small vessels that cause 
damage to the cells. Soluble immune complexes can be deposited in the endothelial 
lining of blood vessel walls in the lung, joints, kidney, and skin. Activation of the 
complement initiates tissue injury. Macrophages and neutrophils further contribute to 
this tissue damage (11). 
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1.2.4. TYPE IV: DELAYED HYPERSENSITIVITY 
Contrary to type I-III, this type of hypersensitivity is cell-mediated. The reaction 
involves antigen-presenting cells that present the antigen to T-lymphocytes which 
results in proliferation and release of cytokines. Symptoms usually develop within 2-
14 days and appear mainly as skin eruptions after exposure to drugs, cosmetics, and 
environmental chemicals (20, 21). To understand the inflammatory processes during 
type IV hypersensitivity these reactions have nowadays been grouped into 4 
subtypes: type IVa: corresponds to Th1 reactions with mainly IFN-γ, IL-1, and IL-2 
production and involves monocytes/macrophages activation; type IVb: corresponds 
to Th2 responses with cytokine production such as IL-5, IL-4, and IL-13 and activates 
eosinophils; type IVc: involves cytotoxic cells and production of perforins and 
granzymes; type IVd: involves T-cells, CD4 and CD8, and neutrophils with cytokine 
production as IL-8 and GM-CSF (22). 
 
1.3. FOOD ALLERGY 
Around 6 to 8% of children younger than 10 years and 1 to 4% of the adult population 
suffer from food allergies, the “Big-8” food allergens are cow’s milk, hen’s egg, soy, 
wheat, peanuts, tree nuts, fish, and shellfish (23, 24).  
Only a very small number of food proteins are responsible for the allergic reactions 
compared to the large quantity of proteins that are consumed every day in a normal 
diet. In young children, mainly milk, eggs, peanuts, soy, and wheat elicit adverse 
reactions, in adults, peanuts, fish, shellfish, and tree nuts trigger allergic reactions. 
The food allergens are characterized as water-soluble glycoproteins, ranging from 10 
to 70 kDa in size with a high stability against heat, acid, and proteases (25). 
Adverse reactions to foods can be classified into true food allergy or non-allergic food 
intolerances. Intolerances to foods are elicited by different components of the food 
such as pharmacological ingredients like monosodium glutamate or histamine, non-
specific mast cell activation by irritating foods such as strawberries or additives or are 
elicited by deficiencies in the host like lactase deficiency (26). Symptoms elicited by 
non-allergic reactions can be flushing, hypotension, urticaria, and in the worst case 
anaphylactoid reactions (27). 
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1.4. COW’S MILK ALLERGY 
The first observations of adverse reactions to cow’s milk were described by 
Hippocrates (prior to 370 B.C.) as urticaria and gastric upset after cow’s milk 
consumption (28). 500 years later, Galen also described a cow’s milk allergic 
reaction (29). In the beginning of this century adverse reactions to cow’s milk were 
described as “idiosyncrasy” and mainly published in the German literature. It was 
Wernstedt, in Sweden, who linked such reactions to allergy (30). Since 1950s, more 
allergic reactions to cow’s milk are described, which might be related to the decrease 
in breast feeding and increase in feeding with cow’s milk based formulas (31, 32). 
Nowadays, cow’s milk allergy is the most prevalent food allergy in the first years of 
life, affecting about 2 to 3% of infants and young children and 0.5% of purely 
breastfed infants in developed countries. Cow’s milk allergy usually appears after 
cow’s milk or a cow’s milk-based formula is introduced into the diet. Cow’s milk 
allergic infants suffer normally from two or more symptoms affecting two or more 
organ systems (Table I).  
 
Table I. Signs and symptoms of cow’s milk allergy (33)  
       
    
Gastrointestinal Vomiting, regurgitation  
 Abdominal pain  
 Colic   
 Diarrhoea   
 Constipation   
 Haemochezia  
Skin Rash   
 Atopic eczema  
 Urticaria   
 Swollen lips   
 Angio-oedema  
 Pruritis   
Respiratory Rhinitis   
 Concuntivits   
 Hoarseness, dysphagia  
 Wheezing, asthma  
General Food refusal   
 Growth retardation  
 Iron-deficient anaemia  
 Irritability, disturbed sleep  
 Apnoea, apparent life-threatening events 
 Anaphylaxis   
        
 
Most cow’s milk allergic infants suffer from gastrointestinal symptoms, around 50-
70% have cutaneous problems, and about 20-30% will suffer from respiratory 
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symptoms. Severe symptoms as anaphylactic reactions appear in the worst case. 
Sixty % of all allergic reactions to cow’s milk are IgE-mediated and around 40% are 
non-IgE-mediated (Fig. 5) (34-36). 
 
 
     Fig 5. Classification of adverse reactions to cow’s milk (24) 
 
The majority of cow’s milk allergic infants outgrow their cow’s milk allergy, 45 to 50% 
at 1 year, 60 to 75% at 2 years, and 85 to 90% at 3 years (34). Unfortunately, many 
of the infants that outgrow cow’s milk allergy develop other atopic diseases as 
asthma, hay fever, or dermatitis to inhalant allergens over the years, also termed 
“atopic march” (37). It is nowadays assumed that the persistency to cow’s milk 
allergy is related to a different IgE-epitope recognition pattern on the cow’s milk 
allergens (38, 39). 
Only 0.1 to 0.5% of adult patients suffer from cow’s milk allergy (40). The majority of 
these patients acquire cow’s milk allergy at adult age, in one third cow’s milk allergy 
persists from infancy. These adult patients are very often strongly allergic to cow’s 
milk, most frequently problems are oropharyngeal symptoms and symptoms of the 
skin. Anaphylactic reactions to cow’s milk seem to appear more often in adults than 
children (41, 42).  
 
1.4.1. COW’S MILK ALLERGENS 
Cow’s milk contains around 30 to 35g of proteins per liter. Through the acidification of 
raw skim milk to pH 4.6 at 20°C two fractions are obtained: caseins that contain 80% 
of total cow’s milk proteins and whey that contains around 20% of the proteins (Table 
II) (43-45). 
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Table II. Characterization of major cow’s milk proteins, adapted after Jost R. (46) 
                  
    Number of Secondary structures  
    amino acid     
Proteins Concentration Size residues S-S bridges (% of total chain)  
(Concentration % milk proteins) (g/l) (kDa) per molecule per molecule α-helix β-sheet pI 
         
Whey (20%) β-Lg (10%) 3-4 18.3 162 2 + 1 free SH +++ 15 5.3 
(~5g/l) α-La (5%) 1-1.5 14.2 123 4 ++ 25 4.8 
 Igs (3%) 0.6-1.0 150      
 BSA (1%) 0.1-0.4 66.3 582 17 + 1 free SH +++ 50 4.9-5.1 
 Lf (traces) 0.09 80 703 16   8.7 
Whole casein (80%) αS1-cas (32%) 12-15 23.6 199  + 4-15 4.9-5 
(~30g/L) αS2-cas (10%) 3-4 25.2 207 1   5.2-5.4 
 β-cas (28%) 9-11 24 209  + 1-10 5.1-5.4 
 κ-cas (10%) 3-4 19 169 1 ++ 14 5.4-5.6 
                  
         
S-S bridge, disulphide bridge; free SH, free cysteine 
 
1.4.1.1. Caseins 
This fraction consists of αS1-casein (αS1-cas), αS2-casein (αS2-cas), β-casein (β-
cas), and κ-casein (κ-cas). The caseins share little sequence homology but share 
features as heat resistance, high lability to proteases and exopeptidases and are 
extensively digested in the gut. The proteins are phosphorylated, the tertiary 
structure is highly hydrated and flexible. Together the four caseins form aggregates, 
micelles that are in suspension in the aqueous phase of the milk (45). 
 
1.4.1.2. Whey 
This fraction is made up of mainly α-lactalbumin (α-la), β-lactoglobulin (β-lg) but also 
contains bovine serum albumin (BSA), immunoglobulin (Ig), and lactoferrin (Lf).  
Alpha-lactalbumin is a small (14.2 kDa), acidic (pI 4.8) monomeric globular protein of 
123 amino residues with a single calcium binding site. The binding of calcium 
stabilizes the secondary structure of the molecule. Alpha-lactalbumin plays an 
important role in the biosynthesis of lactose through the interaction with lactose 
synthase (45). 
Beta-lactoglobulin is a dimeric protein, with 162 amino acids per peptide and a total 
size of 36 kDa. It is the most abundant whey protein in cow’s milk but absent in 
human milk (47). The protein has 2 disulfide bridges that form the typical tertiary 
structure of a retinol-binding protein that belongs to the lipocalin family. The tertiary 
structure of lipocalins is made up of a beta-barrel with 8 or 10 antiparallel beta-
sheets. The protein has a high resistance against proteases in the gut, therefore 
large fragments thereof are presented to immune cells (48, 49). 
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Lactoferrin is an iron-binding glycoprotein with 703 amino acids and a size of 80 kDa 
that belongs to the transferrin family. Besides its function as a scavenger of free 
radicals and an antioxidant, it has antimicrobial properties and positive influence on 
the defence against infections (45). 
Bovine serum albumin has 583 amino acids, a weight of 66.4 kDa and contains 17 
disulfide bonds (45). BSA is physically and immunologically identical to blood serum 
albumin, that plays a role in transport, metabolism, distribution of ligands, osmotic 
pressure of blood and prevention of free radicals (50). 
 
1.4.2. RECOMBINANT COW’S MILK ALLERGENS 
Nowadays more than 40 food allergens are available in recombinant form which 
guarantees standardized quality and also high quantities. For this purpose it is 
necessary to identify relevant allergen sources, isolate mRNA and synthesize cDNA. 
The relevant allergen-encoding cDNAs can be isolated from a cDNA library by 
immunoscreening technology with sera from allergic patients or by a PCR-based 
approach. In the next step, the allergen-encoding cDNAs are inserted into a vector, 
which allows the production of pure and stable allergens that contain the same 
epitopes as natural allergens, using Escherichia coli or other expression systems 
(51). Natural allergen extracts are rarely standardized, so the amounts of allergens 
can differ from one extract to the other, and the immunological activities are also not 
defined. Therefore recombinant allergens have a big advantage over natural extracts, 
they improve diagnosis and facilitate an important progress from extract-based 
diagnosis to a component-resolved diagnosis. With the usage of recombinant purified 
proteins possible cross-reactivities and potential severity of the symptoms can be 
tested (52). Further, recombinant proteins can be modified for immunotherapy so that 
only T-cell epitopes but no B-cell epitopes are recognized during desensitization (53).  
 
1.5. NON-IGE-MEDIATED FOOD ALLERGY 
The immunological mechanisms of non-IgE-mediated food allergy are still unclear 
and since most of the symptoms are delayed (after several hours or days) there are 
always difficulties in connecting the allergy eliciting food with the symptoms. Besides, 
the diagnostic tools for non-IgE-mediated reactions are very limited (54). 
Symptoms affect mainly the gastrointestinal tract (diarrhea, indigestion, bloating, 
loose stool, chronic relapsing reflux, abdominal pain). Pediatric eosinophilic 
14 
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oesophagitis is the most studied non-IgE-mediated food disorder. It is characterized 
by eosinophils that infiltrate the oesophagal epithelia in contrast to eosinophilic 
gastroenteritis where eosinophils are present in the stomach and/ or duodenum (55).  
 
1.6. DIAGNOSIS OF IGE-MEDIATED FOOD ALLERGIES/ COW’S MILK ALLERGY 
The diagnosis of food allergies starts with a detailed history and physical examination 
including possible allergy-eliciting foods, amount of ingested foods, time course of 
reaction, reaction consistency, and additional factors as intake of drugs, exercise, 
and stress. In a next step, different in vitro and in vivo diagnostic tests can be carried 
out as described below: 
 
1.6.1. IN VITRO DIAGNOSTIC TESTS 
1.6.1.1. Determination of serum IgE antibody levels 
Measurement of food-specific IgE can be performed with RAST (radioallergosorbent 
test) or ImmunoCap (Pharmacia, Sweden) testing. Patients’ sera are exposed to 
solid matrix-bound allergens and then detected by a labeled antibody specific for the 
Fc portion of human IgE. The sensitivity of IgE tests is very high. Since these tests 
can deliver irrelevant positive results, the clinical history has to be considered for the 
interpretation of the test results (26, 56). 
A new test system, called microarray technology, enables a thorough analyses of 
several hundreds allergens in one step. Recombinant as well as natural proteins and 
synthetic peptides are dotted on a carrier surface and tested with very small amounts 
of patients’ sera which is especially important in cow’s milk allergy where mainly 
infants are affected (57, 58). These microarrays add new information to patients’ 
individual sensitization profiles including determination of cross reactive allergens 
and may facilitate selection of the right allergens for component resolved 
immunotherapy (CRIT) (59). 
 
1.6.1.2. Basophil mediator release 
Different systems are nowadays established to test if allergens capable of binding 
human IgE also have biological activity in terms of mediator release. Basophils from 
sensitized patients, IgE-depleted stripped basophils from healthy donors, basophil 
cell lines or animal cell lines transfected with human IgE high affinity receptor are 
loaded with patients’ sera containing IgE antibodies and are then stimulated with 
15 
 INTRODUCTION 
allergens. Crosslinking of FcεRI-bound IgE induces the release of histamine, which 
can be measured by radioimmunoassay or enzyme-linked immunosorbent assays. 
Alternatively basophil activation can also be monitored by measurement of the 
surface activation markers CD63 and CD203c (60). 
 
1.6.2. IN VIVO DIAGNOSTIC TESTS  
1.6.2.1. Skin prick test (SPT) 
SPT is a very rapid and cheap possibility to screen patients with suspected food 
allergy. Glycerinated food extracts or fresh extracts and a saline-glycerin control are 
applied by the prick or puncture technique. If the patient has IgE antibodies against 
the food allergen, a wheal at least 3 mm larger than the saline control will appear. 
 
1.6.2.2. Patch testing 
Atopy patch testing (APT) is normally used for diagnosis of delayed-type (cell-
mediated) allergy (61). Commercial preparations for APT or fresh food allergen 
sources are applied externally, normally at the back of the patients for up to 24 hours 
and skin reactions are documented after another 24 to 48 hours (62).  
 
1.6.2.3. Oral food challenge (open or double blind) 
Food challenges are very important tools when the diagnosis of cow’s milk allergy 
remains uncertain (33, 63). Patients consume increasing quantities of the suspected 
food and the challenge is stopped as soon as adverse reactions appear or after a 
considerable amount has been consumed without reactions. An open food challenge 
(not double blind or placebo controlled) can be used to confirm negative diagnostic 
results, in case of positive diagnostic results a double blind, placebo controlled food 
challenge (DBPCFC) should be applied (27). Since oral food challenges are time 
consuming, costly, and bear the risk of inducing strong adverse reactions, some 
studies investigate how predictive specific IgE tests are and if they can replace oral 
food challenges (64-66). 
 
1.7. TREATMENT OF COW’S MILK ALLERGY 
1.7.1. Avoidance of allergens 
At the moment, the most frequently recommended treatment of cow’s milk allergy is 
the elimination of cow’s milk from the daily nutrition after obtaining a detailed clinical 
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history and after identification of cow’s milk as the allergy-eliciting food component 
(33). Physicians need to keep the improvement of symptoms, nutritional deficiencies, 
increase in cost and time in mind when they choose an appropriate diet (67). 
Management of cow’s milk allergy can also include a special diet for nursing mothers 
and the usage of substitutions based on extensively hydrolyzed cow’s milk for cow’s 
milk allergic infants (26, 68, 69). 
 
1.7.2. Food allergy prevention 
The European and American recommendations indicate that children with atopic risk 
should be exclusively breast fed for 4-6 months, followed by delayed introduction of 
solid foods. There is no confirmation that avoidance of antigens by the mothers 
during pregnancy or lactation has shown a positive influence on atopic disease 
prevention (70, 71). 
 
1.7.3. Emergency treatment 
This treatment needs to be explained very carefully by the physician and normally 
includes oral anthistamine for mild reactions affecting the skin or the gut and self-
injectable adrenaline for systemic or respiratory reactions (26). 
 
1.7.4. Immunotherapy  
Subcutaneous immunotherapy as routinely used for treatment of cat allergy, venom 
allergy, and several respiratory allergies is very rarely used for the treatment of food 
allergy where the risk of severe systemic reactions is too high (72, 73). Therefore oral 
immunotherapy, which induces tolerance by exposing the patient to increasing 
amounts of the food antigen via the mucosal route, has become the favored therapy 
(74, 75). Promising improvements in life quality were demonstrated especially in 
patients with severe and persistent cow’s milk allergy (76, 77).  
Sublingual immunotherapy, where the antigen is kept under the tongue for some 
minutes before it is swallowed, is mainly used for treatment of respiratory allergy and 
very rarely applied for treatment of peanut allergy or cow’s milk allergy (78, 79). 
Immunomodulatory treatment with anti-IgE molecules has been tested for peanut 
allergy. However, the safety concerns were very high and the outcome of the study 
was not so promising (80). 
17 
 INTRODUCTION 
References 
1. Avenberg, K. M., D. S. Harper, and B. L. Larsson. 1986. Footnotes on allergy. 
Pharmacia, Uppsala, Sweden. 
2. Jackson, M. 2006. Allergy: The History of a Modern Malady. London: Reaktion 
Books: pp. 288. 
3. Bostock, J. 1960. Case of a periodical affection of the eyes and chest. Ann 
Allergy 18:894-895. 
4. Blackley, C. 1873. Experimental researches on the cause and nature of hay 
fever. Balliere, Tindall & Cox, London. 
5. Richet, G. 1999. [Nobel prize to Charles Richet in 1913 and the first 12 years 
of anaphylaxis]. Rev Prat 49:1957-1960. 
6. Pirquet, v. 1906. Allergie. Münch Med Wochenschr 53:1457-1458. 
7. Johansson, S. G., T. Bieber, R. Dahl, P. S. Friedmann, B. Q. Lanier, R. F. 
Lockey, C. Motala, J. A. Ortega Martell, T. A. Platts-Mills, J. Ring, F. Thien, P. 
Van Cauwenberge, and H. C. Williams. 2004. Revised nomenclature for 
allergy for global use: Report of the Nomenclature Review Committee of the 
World Allergy Organization, October 2003. J Allergy Clin Immunol 113:832-
836. 
8. Ring, J. 2005. Allergy in practice. Springer, Berlin Heidelberg New York:296 p. 
174 illus. 
9. Ishizaka, K., and T. Ishizaka. 1967. Identification of gamma-E-antibodies as a 
carrier of reaginic activity. J Immunol 99:1187-1198. 
10. Johansson, S. G., H. Bennich, and L. Wide. 1968. A new class of 
immunoglobulin in human serum. Immunology 14:265-272. 
11. Coombs, R. R. A., and P. G. H. Gell. Classification of allergic reactions 
responsible for clinical hypersensitivity and disease. In: Gell P. G. H., Coombs 
R. R. A., Lachmann P. J. eds. Clinical aspects of immunology. 3rd ed. Oxford: 
Blackwall Scientific Publications, 1975, pp 761-781. 
12. Murphy, K., P. Travers, and M. Walport. In Janeway's immunobiology; 7th ed. 
New York: Garland Science, 2008: 887 pp.  
13. Floistrup, H., J. Swartz, A. Bergstrom, J. S. Alm, A. Scheynius, M. van Hage, 
M. Waser, C. Braun-Fahrlander, D. Schram-Bijkerk, M. Huber, A. Zutavern, E. 
von Mutius, E. Ublagger, J. Riedler, K. B. Michaels, G. Pershagen, and G. The 
Parsifal Study. 2006. Allergic disease and sensitization in Steiner school 
children. J Allergy Clin Immunol 117:59-66. 
14. Kulig, M., R. Bergmann, U. Klettke, V. Wahn, U. Tacke, and U. Wahn. 1999. 
Natural course of sensitization to food and inhalant allergens during the first 6 
years of life. J Allergy Clin Immunol 103:1173-1179. 
15. Niederberger, V., B. Niggemann, D. Kraft, S. Spitzauer, and R. Valenta. 2002. 
Evolution of IgM, IgE and IgG(1-4) antibody responses in early childhood 
monitored with recombinant allergen components: implications for class switch 
mechanisms. Eur J Immunol 32:576-584. 
16. Sporik, R., S. T. Holgate, T. A. Platts-Mills, and J. J. Cogswell. 1990. Exposure 
to house-dust mite allergen (Der p I) and the development of asthma in 
childhood. A prospective study. N Engl J Med 323:502-507. 
17. Platts-Mills, T., J. Vaughan, S. Squillace, J. Woodfolk, and R. Sporik. 2001. 
Sensitisation, asthma, and a modified Th2 response in children exposed to cat 
allergen: a population-based cross-sectional study. Lancet 357:752-756. 
18. Braun-Fahrlander, C., J. Riedler, U. Herz, W. Eder, M. Waser, L. Grize, S. 
Maisch, D. Carr, F. Gerlach, A. Bufe, R. P. Lauener, R. Schierl, H. Renz, D. 
18 
 INTRODUCTION 
Nowak, and E. von Mutius. 2002. Environmental exposure to endotoxin and its 
relation to asthma in school-age children. N Engl J Med 347:869-877. 
19. Larche, M., C. A. Akdis, and R. Valenta. 2006. Immunological mechanisms of 
allergen-specific immunotherapy. Nat Rev Immunol 6:761-771. 
20. Krasteva, M. 1993. Contact dermatitis. Int J Dermatol 32:547-560. 
21. Storrs, F. J. 1991. Contact dermatitis caused by drugs. Immunol. Allergy Clin. 
N. Am. 11:509-523. 
22. Czarnobilska, E., K. Obtulowicz, and K. Wsolek. 2007. [Type IV of 
hypersensitivity and its subtypes]. Przegl Lek 64:506-508. 
23. Bischoff, S., and S. E. Crowe. 2005. Gastrointestinal food allergy: new insights 
into pathophysiology and clinical perspectives. Gastroenterology 128:1089-
1113. 
24. Crittenden, R. G., and L. E. Bennett. 2005. Cow's milk allergy: a complex 
disorder. J Am Coll Nutr 24:582S-591S. 
25. Sampson, H. A. 1999. Food allergy. Part 1: immunopathogenesis and clinical 
disorders. J Allergy Clin Immunol 103:717-728. 
26. Benhamou, A. H., M. G. Schappi Tempia, D. C. Belli, and P. A. Eigenmann. 
2009. An overview of cow's milk allergy in children. Swiss Med Wkly 139:300-
307. 
27. Bindslev-Jensen, C. 1998. Food allergy. Bmj 316:1299-1302. 
28. Chabot, R. 1951. Pediatric Allergy. New York: MacGraw-Hill. 
29. O’Keefe, E. S. 1953. The history of infants feeding. II. Seventeenth and 
eighteenth centuries. Arch Dis Child 28:232-240. 
30. Wernstedt, W. 1910. Zur Frage der Kuhmilchidiosynkrasie im Säuglingsalter. 
Monatschr Kinderheilkunde 9:25-26. 
31. Savilahti, E. 1981. Cow's milk allergy. Allergy 36:73-88. 
32. Hamburger, R. N. 1989. Introduction: a brief history of food allergy with 
definitions of terminology in food intolerance. In Hamburger RN, Ed. Food 
Intolerance in Infancy. New York: Raven Press:1-6. 
33. Kneepkens, C. M., and Y. Meijer. 2009. Clinical practice. Diagnosis and 
treatment of cow's milk allergy. Eur J Pediatr 168:891-896. 
34. Host, A. 2002. Frequency of cow's milk allergy in childhood. Ann Allergy 
Asthma Immunol 89:33-37. 
35. Sampson, H. A., S. H. Sicherer, and A. H. Birnbaum. 2001. AGA technical 
review on the evaluation of food allergy in gastrointestinal disorders. American 
Gastroenterological Association. Gastroenterology 120:1026-1040. 
36. Kagan, R. S. 2003. Food allergy: an overview. Environ Health Perspect 
111:223-225. 
37. Spergel, J. M., and A. S. Paller. 2003. Atopic dermatitis and the atopic march. 
J Allergy Clin Immunol 112:S118-127. 
38. Vila, L., K. Beyer, K. M. Jarvinen, P. Chatchatee, L. Bardina, and H. A. 
Sampson. 2001. Role of conformational and linear epitopes in the 
achievement of tolerance in cow's milk allergy. Clin Exp Allergy 31:1599-1606. 
39. Jarvinen, K. M., K. Beyer, L. Vila, P. Chatchatee, P. J. Busse, and H. A. 
Sampson. 2002. B-cell epitopes as a screening instrument for persistent cow's 
milk allergy. J Allergy Clin Immunol 110:293-297. 
40. Woods, R. K., F. Thien, J. Raven, E. H. Walters, and M. Abramson. 2002. 
Prevalence of food allergies in young adults and their relationship to asthma, 
nasal allergies, and eczema. Ann Allergy Asthma Immunol 88:183-189. 
41. Host, A., and S. Halken. 1990. A prospective study of cow milk allergy in 
Danish infants during the first 3 years of life. Clinical course in relation to 
19 
 INTRODUCTION 
clinical and immunological type of hypersensitivity reaction. Allergy 45:587-
596. 
42. Lam, H. Y., E. van Hoffen, A. Michelsen, K. Guikers, C. H. van der Tas, C. A. 
Bruijnzeel-Koomen, and A. C. Knulst. 2008. Cow's milk allergy in adults is rare 
but severe: both casein and whey proteins are involved. Clin Exp Allergy 
38:995-1002. 
43. Jenness, R. 1979. Comparative aspects of milk proteins. J Dairy Res 46:197-
210. 
44. Wal, J. M. 2001. Structure and function of milk allergens. Allergy 56 Suppl 
67:35-38. 
45. Wal, J. M. 2002. Cow's milk proteins/allergens. Ann Allergy Asthma Immunol 
89:3-10. 
46. Jost, R. 1988. Physicochemical treatment of food allergens: application to 
cow's milk proteins. Nestle Nutrition Workshop Series 17:187-197. 
47. Taheri-Kafrani, A., J. C. Gaudin, H. Rabesona, C. Nioi, D. Agarwal, M. Drouet, 
J. M. Chobert, A. K. Bordbar, and T. Haertle. 2009. Effects of heating and 
glycation of beta-lactoglobulin on its recognition by IgE of sera from cow milk 
allergy patients. J Agric Food Chem 57:4974-4982. 
48. Papiz, M. Z., L. Sawyer, E. E. Eliopoulos, A. C. North, J. B. Findlay, R. 
Sivaprasadarao, T. A. Jones, M. E. Newcomer, and P. J. Kraulis. 1986. The 
structure of beta-lactoglobulin and its similarity to plasma retinol-binding 
protein. Nature 324:383-385. 
49. Wal, J. M. 2004. Bovine milk allergenicity. Ann Allergy Asthma Immunol 
93:S2-11. 
50. Farrell, H. M., Jr., R. Jimenez-Flores, G. T. Bleck, E. M. Brown, J. E. Butler, L. 
K. Creamer, C. L. Hicks, C. M. Hollar, K. F. Ng-Kwai-Hang, and H. E. 
Swaisgood. 2004. Nomenclature of the proteins of cows' milk--sixth revision. J 
Dairy Sci 87:1641-1674. 
51. Valenta, R., S. Vrtala, S. Laffer, S. Spitzauer, and D. Kraft. 1998. 
Recombinant allergens. Allergy 53:552-561. 
52. Bohle, B., and S. Vieths. 2004. Improving diagnostic tests for food allergy with 
recombinant allergens. Methods 32:292-299. 
53. Valenta, R. 2002. The future of antigen-specific immunotherapy of allergy. Nat 
Rev Immunol 2:446-453. 
54. Jyonouchi, H. 2008. Non-IgE mediated food allergy. Inflamm Allergy Drug 
Targets 7:173-180. 
55. Chehade, M. 2007. IgE and non-IgE-mediated food allergy: treatment in 2007. 
Curr Opin Allergy Clin Immunol 7:264-268. 
56. Sicherer, S. H., and D. Y. Leung. 2006. Advances in allergic skin disease, 
anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects. J 
Allergy Clin Immunol 118:170-177. 
57. Hiller, R., S. Laffer, C. Harwanegg, M. Huber, W. M. Schmidt, A. Twardosz, B. 
Barletta, W. M. Becker, K. Blaser, H. Breiteneder, M. Chapman, R. Crameri, 
M. Duchene, F. Ferreira, H. Fiebig, K. Hoffmann-Sommergruber, T. P. King, T. 
Kleber-Janke, V. P. Kurup, S. B. Lehrer, J. Lidholm, U. Muller, C. Pini, G. 
Reese, O. Scheiner, A. Scheynius, H. D. Shen, S. Spitzauer, R. Suck, I. 
Swoboda, W. Thomas, R. Tinghino, M. Van Hage-Hamsten, T. Virtanen, D. 
Kraft, M. W. Muller, and R. Valenta. 2002. Microarrayed allergen molecules: 
diagnostic gatekeepers for allergy treatment. Faseb J 16:414-416. 
20 
 INTRODUCTION 
58. Harwanegg, C., S. Laffer, R. Hiller, M. W. Mueller, D. Kraft, S. Spitzauer, and 
R. Valenta. 2003. Microarrayed recombinant allergens for diagnosis of allergy. 
Clin Exp Allergy 33:7-13. 
59. Valenta, R., J. Lidholm, V. Niederberger, B. Hayek, D. Kraft, and H. Gronlund. 
1999. The recombinant allergen-based concept of component-resolved 
diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy 29:896-
904. 
60. Kleine-Tebbe, J., S. Erdmann, E. F. Knol, D. W. MacGlashan, Jr., L. K. 
Poulsen, and B. F. Gibbs. 2006. Diagnostic tests based on human basophils: 
potentials, pitfalls and perspectives. Int Arch Allergy Immunol 141:79-90. 
61. Turjanmaa, K., U. Darsow, B. Niggemann, F. Rance, T. Vanto, and T. Werfel. 
2006. EAACI/GA2LEN position paper: present status of the atopy patch test. 
Allergy 61:1377-1384. 
62. Ballabio, C., A. Fiocchi, A. Martelli, S. Pecora, S. E. Burastero, and P. Restani. 
2009. A method for the analysis of milk and egg allergens for the atopy patch 
test. Exp Dermatol. 
63. Niggemann, B., B. Sielaff, K. Beyer, C. Binder, and U. Wahn. 1999. Outcome 
of double-blind, placebo-controlled food challenge tests in 107 children with 
atopic dermatitis. Clin Exp Allergy 29:91-96. 
64. Garcia-Ara, M. C., M. T. Boyano, J. M. Diaz-Pena, and S. Quirce. 2008. 
Eliciting doses of positive challenge test in cow's milk allergy are related to 
cow's milk specific IgE levels. Allergol Immunopathol (Madr) 36:315-319. 
65. Martorell, A., M. C. Garcia Ara, A. M. Plaza, J. Bone, S. Nevot, L. Echeverria, 
E. Alonso, and J. Garde. 2008. The predictive value of specific 
immunoglobulin E levels in serum for the outcome of the development of 
tolerance in cow's milk allergy. Allergol Immunopathol (Madr) 36:325-330. 
66. Rottem, M., D. Shostak, and S. Foldi. 2008. The predictive value of specific 
immunoglobulin E on the outcome of milk allergy. Isr Med Assoc J 10:862-
864. 
67. Baral, V. R., and J. O. Hourihane. 2005. Food allergy in children. Postgrad 
Med J 81:693-701. 
68. Brill, H. 2008. Approach to milk protein allergy in infants. Can Fam Physician 
54:1258-1264. 
69. Restani, P., C. Ballabio, C. Di Lorenzo, S. Tripodi, and A. Fiocchi. 2009. 
Molecular aspects of milk allergens and their role in clinical events. Anal 
Bioanal Chem 395:47-56. 
70. Kramer, M. S., and R. Kakuma. 2006. Maternal dietary antigen avoidance 
during pregnancy or lactation, or both, for preventing or treating atopic disease 
in the child. Cochrane Database Syst Rev 3:CD000133. 
71. Greer, F. R., S. H. Sicherer, and A. W. Burks. 2008. Effects of early nutritional 
interventions on the development of atopic disease in infants and children: the 
role of maternal dietary restriction, breastfeeding, timing of introduction of 
complementary foods, and hydrolyzed formulas. Pediatrics 121:183-191. 
72. Calderon, M. A., B. Alves, M. Jacobson, B. Hurwitz, A. Sheikh, and S. 
Durham. 2007. Allergen injection immunotherapy for seasonal allergic rhinitis. 
Cochrane Database Syst Rev:CD001936. 
73. Muller, U., D. B. Golden, R. F. Lockey, and B. Shin. 2008. Immunotherapy for 
hymenoptera venom hypersensitivity. Clin Allergy Immunol 21:377-392. 
74. Skripak, J. M., and H. A. Sampson. 2008. Towards a cure for food allergy. 
Curr Opin Immunol 20:690-696. 
21 
 INTRODUCTION 
22 
75. Skripak, J. M., and R. A. Wood. 2009. Mammalian milk allergy: avoidance 
strategies and oral desensitization. Curr Opin Allergy Clin Immunol 9:259-264. 
76. Beyer, K., and U. Wahn. 2008. Oral immunotherapy for food allergy in 
children. Curr Opin Allergy Clin Immunol 8:553-556. 
77. Caminiti, L., G. Passalacqua, S. Barberi, D. Vita, G. Barberio, R. De Luca, and 
G. Battista. 2009. A new protocol for specific oral tolerance induction in 
children with IgE-mediated cow's milk allergy. Allergy Asthma Proc. 
78. Staden, U., K. Blumchen, N. Blankenstein, N. Dannenberg, H. Ulbricht, K. 
Dobberstein, M. Ziegert, B. Niggemann, U. Wahn, and K. Beyer. 2008. Rush 
oral immunotherapy in children with persistent cow's milk allergy. J Allergy Clin 
Immunol 122:418-419. 
79. de Boissieu, D., and C. Dupont. 2006. Sublingual immunotherapy for cow's 
milk protein allergy: a preliminary report. Allergy 61:1238-1239. 
80. Leung, D. Y., H. A. Sampson, J. W. Yunginger, A. W. Burks, Jr., L. C. 
Schneider, C. H. Wortel, F. M. Davis, J. D. Hyun, and W. R. Shanahan, Jr. 
2003. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 
348:986-993. 
 
 
 
 
 AIM OF THE THESIS & DECLARATION OF CONTRIBUTION 
Aim of the thesis & declaration of the contribution on the 
manuscripts 
 
The main focus of the work was the molecular characterization and epitope mapping 
of important allergens and the investigation of immune responses to cow’s milk 
allergens.  
 
Two important cow’s milk proteins were analyzed in detail, alpha-lactalbumin that 
belongs to the whey fraction and alphaS1-casein that belongs to the casein fraction 
of cow’s milk. Based on these studies, tools for better diagnosis of cow’s milk allergy 
were developed. The expression, biochemical characterization, IgE reactivity, and 
allergenic activity of alpha-lactalbumin are described in manuscript 1 and of 
alphaS1-casein in manuscript 2.  
 
Manuscript 1: H. Hochwallner, U. Schulmeister, I. Swoboda, M. Focke-Tejkl, V. 
Civaj, N. Balic, M. Nystrand, A. Härlin, J. Thalhamer, S. Scheiblhofer, W. Keller, T. 
Pavkov, B. Niggemann, S. Quirce, A. Mari, G. Pauli, C. Ebner, N.G. Papadopoulos, 
U. Herz, E.A.F. van Tol, R. Valenta, and S. Spitzauer. Molecular Characterization, 
IgE Epitope Mapping, and Assessment of Allergenic Activity of Recombinant Alpha-
Lactalbumin, a Major Cow’s Milk Allergen. (Submitted) 
 
Contribution: 
Expression of recombinant protein, analysis of IgE binding properties, calcium 
depletion experiments, analysis of data, writing of the manuscript 
80 percent 
 
Manuscript 2: U. Schulmeister, H. Hochwallner, I. Swoboda, M. Focke-Tejkl, B. 
Geller, M.Nystrand, A. Härlin, J. Thalhamer, S. Scheiblhofer, W. Keller, B. 
Niggemann, S. Quirce, C. Ebner, A. Mari, G. Pauli, U. Herz, R. Valenta, and S. 
Spitzauer. Cloning, Expression, and Mapping of Allergenic Determinants of alphaS1-
Casein, a Major Cow’s Milk Allergen. J Immunol. 2009 Jun 1;182(11):7019-29 
 
 
 
23 
 AIM OF THE THESIS & DECLARATION OF CONTRIBUTION 
24 
Contribution: 
Expression and purification of the protein, contribution to the analysis of the data and 
to the preparation of the manuscript 
50 percent 
 
In manuscript 3 we established an assay that combined IgE-reactivity testing of 
recombinant milk allergen components by microarray and basophil degranulation and 
analyzed IgE reactivity as well as allergenic activity to individual cow’s milk allergens 
in a large cohort of cow’s milk allergic patients. 
 
Manuscript 3: H. Hochwallner,* U. Schulmeister,* I. Swoboda, B. Geller, M. 
Nystrand, A. Härlin, J. Thalhamer, S. Scheiblhofer, B. Niggemann, S. Quirce, C. 
Ebner, A. Mari, G. Pauli, U. Herz, E. A.F. van Tol, R. Valenta, and S. Spitzauer. 
Microarray and Allergenic Activity Assessment of Milk Allergens. *These authors 
contributed equally to this work. (Submitted) 
 
Contribution: 
Expression and purification of recombinant proteins, analysis of microarray-data and 
results from the basophil activation tests, writing of the manuscript   
70 percent 
 
Finally, in manuscript 4 we focussed on the investigation of non-IgE-mediated cow’s 
milk hypersensitivities and we tested whether these adverse reactions can be 
diagnosed based on IgG subclass and IgE measurements to the individual cow’s milk 
allergens.  
 
Manuscript 4: H. Hochwallner, U. Schulmeister, I. Swoboda, M. Kundi, H. 
Vogelsang, L. Kazemi-Shirazi, S. Quirce, N. Balic, R. Valenta, and S.Spitzauer. 
Patients suffering from Non-IgE-Mediated Cow’s Milk Intolerance cannot be 
diagnosed based on IgG-Subclass or IgA Responses to Milk Allergens. (Submitted) 
 
Contribution: 
Design of study, ELISA analysis, immunoblot experiments, writing of the manuscript 
85 percent 
 MANUSCRIPT 1 
2. Molecular Characterization, IgE Epitope Mapping, and 
Assessment of Allergenic Activity of Recombinant Alpha-
Lactalbumin, a Major Cow’s Milk Allergen 
 
Heidrun Hochwallner, Ulrike Schulmeister, Ines Swoboda, Margarete Focke-Tejkl, 
Vera Civaj, Nadja Balic, Mats Nystrand, Annika Härlin, Josef Thalhamer, Sandra 
Scheiblhofer, Walter Keller, Tea Pavkov, Bodo Niggemann, Santiago Quirce, Adriano 
Mari, Gabrielle Pauli, Christoph Ebner, Nikolaos G. Papadopoulos, Udo Herz, Eric 
A.F. van Tol, Rudolf Valenta, and Susanne Spitzauer 
 
 
Submitted, 2009 
25 
  
26 
 MANUSCRIPT 1 
Molecular Characterization, IgE Epitope Mapping, and Assessment of 
Allergenic Activity of Recombinant Alpha-Lactalbumin, a Major Cow’s Milk 
Allergen1  
 
Running title: Characterization of Cow’s Milk Allergen Alpha-Lactalbumin 
 
Heidrun Hochwallner,* Ulrike Schulmeister,* Ines Swoboda,† Margarete Focke-Tejkl,† 
Vera Civaj,† Nadja Balic,* Mats Nystrand,‡ Annika Härlin,‡ Josef Thalhamer,§ Sandra 
Scheiblhofer,§ Walter Keller,¶ Tea Pavkov,¶ Bodo Niggemann,║ Santiago Quirce,# 
Adriano Mari,** Gabrielle Pauli,†† Christoph Ebner,‡‡ Nikolaos G. Papadopoulos,§§ 
Udo Herz,¶¶ Eric A.F. van Tol,¶¶ Rudolf Valenta,† and Susanne Spitzauer* 
 
*Department of Medical and Chemical Laboratory Diagnostics, †Christian Doppler 
Laboratory for Allergy Research, Division of Immunopathology, Department of 
Pathophysiology, Medical University of Vienna, Austria; ‡Phadia, AB, Uppsala, 
Sweden; §Christian Doppler Laboratory for Allergy Diagnosis & Therapy, Department 
of Molecular Biology, University of Salzburg, Austria; ¶Institute of Molecular 
Biosciences, Structural Biology, University of Graz, Austria; ║Department of Pediatric 
Allergology and Pneumology, Hedwig-von-Rittberg-Zentrum, DRK-Kliniken, Berlin, 
Germany; #Allergy Department, Hospital La Paz, Madrid, Spain; **Center for Clinical 
and Experimental Allergology IDI-IRCCS, Rome, Italy; ††Service de Pneumologie, 
Hôpitaux Universitaires, Strasbourg, France; ‡‡Allergy Clinic Reumannplatz, Vienna, 
Austria; §§Allergy Department, 2nd Pediatric Clinic, University of Athens, Greece; 
¶¶Mead Johnson Nutrition, Evansville, USA.  
 
Keywords: Allergy, Antigens/Peptides/Epitopes, Molecular Biology 
 
1This study was supported by research Grants F01804, F01805, and F01815 from 
the Austrian Science Foundation and by research grants from Biomay, Vienna, 
Austria and Mead Johnson Nutrition, Evansville, USA. 
 
Address correspondence and reprint requests to Dr. Rudolf Valenta, Christian 
Doppler Laboratory for Allergy Research, Division of Immunopathology, Department 
of Pathophysiology, Medical University of Vienna, AKH Ebene 3Q, Waehringer 
27 
 MANUSCRIPT 1 
Guertel 18-20, 1090 Vienna, Austria. E-mail address: 
Rudolf.Valenta@meduniwien.ac.at, Phone: +43-1-40400-5108, Fax: +43-1-40400-
5130 
28 
 MANUSCRIPT 1 
Abstract 
Cow’s milk allergy is the most common cause of IgE-mediated hypersensitivity 
reactions in infancy. We isolated a cDNA coding for α-lactalbumin (α-La), a calcium-
binding allergen belonging to the whey fraction of cow’s milk, from a mammary gland 
cDNA library. The α-La cDNA coding for a 14.1 kDa protein was expressed as 
recombinant protein (rα-La) in Escherichia coli and was purified to homogeneity. 
According to circular dichroism analysis the allergen represented a folded protein 
with a high thermal stability and refolding capacity. Micro-arrayed rα-La reacted with 
IgE antibodies from 57.6% of cow’s milk allergic patients (n=66) and hence 
represents a major cow’s milk allergen. The reduction of IgE reactivity by depletion of 
protein-bound calcium suggested the presence of conformational IgE epitopes. Using 
eight synthetic peptides of 19-20 amino acids spanning the complete α-La sequence, 
sequential IgE epitopes rich in surface-exposed amino acids were identified which 
clustered at the N- and C-terminus of the protein. A superposition of the peptides 
onto the three-dimensional structure of α-La revealed a close vicinity of the N- and C-
terminal peptides within one surface-exposed patch. rα-La induced strongest 
degranulation of rat basophil leukaemia cells transfected with human FcεRI when 
cells were loaded with serum IgE from cow’s milk allergic patients who had exhibited 
gastrointestinal symptoms or severe systemic reactions upon cow’s milk exposure. 
rα-La may be used for the diagnosis of patients suffering from severe allergic 
reactions to cow’s milk and serve as a paradigmatic tool for the development of 
therapeutic strategies for cow’s milk allergy. 
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Introduction 
Food allergies are an important health problem worldwide with increasing incidences 
and can be responsible for life-threatening anaphylactic reactions (1). Up to 11% of 
children and approximately 2% of the adult population experience food-induced 
allergic disorders (2, 3). Cow’s milk is the first component introduced into the diet and 
it is the most common cause of food allergy in young children under five years of 
age, affecting about 2 to 3% of infants and young children in developed countries (3, 
4). 
Acute reactions to cow’s milk are mediated by activation of mast cells and basophils 
by IgE-allergen immune complexes (5, 6). In addition, cow’s milk allergens and 
peptides thereof can induce T cell-mediated inflammation (7). Both types of immune 
responses affect the gut but also other target organs such as the skin and the 
respiratory tract. Depending on the involved immune mechanisms, they may result in 
different manifestations, i.e., acute or delayed type reactions (e.g., IgE-mediated: 
acute gut symptoms, rhinitis, asthma, urticaria, and anaphylactic shock; T-cell-
mediated: delayed gut symptoms, chronic asthma, and atopic dermatitis) (8). 
The development of allergic sensitization to cow’s milk allergens and allergen 
sensitivity may depend on several factors including exposure, dose, genetic 
background of the host as well as environmental influences (9-12) and is modulated 
by immunological control mechanisms such as regulatory T cells and effector cell 
sensitivity (13, 14). 
Cow’s milk contains 30 to 35 g of proteins per liter which can be separated using 
biochemical techniques into a casein fraction that contains 80% of total cow’s milk 
proteins and a whey fraction that contains approximately 20% of the proteins. The 
casein fraction contains αS1-, αS2-, β-, and κ-casein, the whey fraction comprises α-
lactalbumin, β-lactoglobulin, bovine serum albumin, lactoferrin, and immunoglobulins 
(15). These proteins are known to elicit an allergic immune response but data 
regarding the frequency of IgE sensitization and the magnitude of the allergic 
immune response towards the individual allergens show considerable variability or 
are lacking (16-19). 
Several studies have identified αS1-casein as a major cow’s milk allergen which 
induces strong immediate as well as delayed type allergic reactions (19, 20, 21). 
Despite that αS1-casein represents a class I food allergen, it was found to contain 
conformational as well as sequential IgE epitopes (19). β-lactoglobulin represents 
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another important cow’s milk allergen which is recognized by approximately 50% of 
cow’s milk allergic patients and for which IgE- as well as T cell epitopes have been 
studied (22-25). However, for α-La a widely varying prevalence of IgE recognition 
ranging from 6% to 100% has been reported in the literature (17, 18, 20, 21, 26, 27). 
α-La plays an important role in the biosynthesis of lactose through the interaction with 
lactose synthase (28). It is expressed exclusively during lactation in the mammary 
gland and accounts for 20% of bovine whey, the remaining 80% being mostly β-
lactoglobulin (29). 
In this paper, we report the isolation of a cDNA coding for α-La, the expression of the 
recombinant allergen in Escherichia coli and its purification to homogeneity. rα-La 
was characterized regarding its fold by circular dichroism and a mapping of 
sequential as well as conformational IgE epitopes was performed to localize the 
major IgE epitopes on the three dimensional structure of the allergen. Using IgE 
microarray technology and the transfer of serum IgE from cow’s milk allergic patients 
with defined clinical symptoms to rat basophils transfected with the human FcεRI the 
IgE reactivity and allergenic activity of rα-La was determined and related to clinical 
manifestations. 
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Materials and Methods 
 
Isolation of an IgE-reactive cDNA coding for α-La and sequence analysis 
The cDNA coding for mature α-La without N-terminal signal sequence and with a C-
terminal hexahistidine tag (rα-La) was obtained by PCR-amplification using a cow’s 
mammary gland cDNA library as template (19). PCR amplification of the cDNA was 
done with the Pfu DNA polymerase system from Fermentas (Fermentas Life 
Sciences, Vilnius, Lithuania) and the following oligonucleotides (MWG Biotech, 
Ebersberg, Germany): α-La 5’: 5’–GCGGATCCACATATGGAACAGTTAACAAAATG 
TGAG– 3’ (NdeI underlined); α-La 3’: 5’–CGGAATTCCTGCAGAACTCAGTGATGAT 
GATGATGATGCAACTTCTCACAGAGCCACTGATCCAGC–3’ (EcoRI underlined; 
His tag-encoding DNA: italics). The PCR product was gel purified and cloned into the 
NdeI/ EcoRI digested expression vector pET 17b (Novagen, Cambridge, UK). The 
sequence was verified by automated sequencing of both DNA strands (VBC 
Genomics, Vienna, Austria).  
The deduced protein sequence of α-La from cow (Bt) as determined by us and the 
protein sequences from α-La of other mammalian species which had been obtained 
from the NIH database (http://www.ncbi.nlm.nih.gov) were aligned manually in Fig. 1 
for maximal fit. Potential glycosylation sites were predicted with a NetNGlyc 1.0 
Server-Program (http://www.cbs.dtu.dk/services/NetNGlyc/). 
 
Expression and purification of rα-La  
For expression of rα-La the E. coli strain BL 21 Codon Plus (DE3)-RIPL (Stratagene, 
La Jolla, CA) was transformed with the α-La-pET 17b plasmid. Bacteria were grown 
in Luria Broth medium containing 100 mg/l ampicillin (Sigma-Aldrich, Vienna, Austria) 
and 50 mg/l chloramphenicol (Sigma-Aldrich) at 37°C to an OD (600 nm) of 0.4-0.6. 
Protein expression was induced by addition of isopropyl-ß-D-thiogalactoside (IPTG, 
Roche, Mannheim, Germany) to a final concentration of 0.5 mM and growing of the 
bacteria for additional 3h at 37°C. Bacteria were harvested by centrifugation, 
bacterial cells were lysed by repeated freeze thaw cycles, and proteins were 
solubilized in urea buffer by stirring (8 M urea, 0.1 M NaH2PO4, 0.01 M Tris-HCl, pH 
8). rα-La was purified under denaturing conditions using Ni-NTA resin affinity 
columns according to the manufacturer’s instructions (QIAGEN, Hilden, Germany). 
Fractions containing the recombinant allergen were pooled, desalted and the buffer 
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was exchanged against 10 mM Tris buffer (pH 8.5) with a PD-10 column (Sephadex, 
GE Healthcare, Uppsala, Sweden). The protein concentration was determined with a 
Micro BCA Protein Assay Kit (Pierce, Rockford, IL) using bovine serum albumin as a 
standard. The purity was analyzed by SDS-PAGE (30) and Coomassie Brilliant Blue 
staining (Biorad, Hercules, CA). 
To confirm the identity of his-tagged rα-La, the protein was blotted onto nitrocellulose 
(31) and incubated with an anti-hexahistidine antibody (Histidin-Tag, Dianova, 
Hamburg, Germany) 1:1000 diluted in PBST over night, and detected with 125I-
labeled sheep anti-mouse IgG antibody (GE Healthcare), diluted 1:1000 in PBST.  
 
Matrix-assisted laser desorption and ionization-time of flight mass spectrometry of  
rα-La 
Laser desorption mass spectra were obtained in a linear mode with a time-of-flight 
Compact MALDI II instrument (Kratos, Manchester, U.K.; piCHEM, R&D, Graz, 
Austria). The protein was dissolved in 10% acetonitrile, 0.1% trifluoroacetic acid) and 
α-cyano-4 hydroxy-cinnamic acid (dissolved in 60% acetonitrile, 0.1% trifluoroacetic 
acid) was used as a matrix. For the preparation of the sample a 1:2 mixture of protein 
and matrix solution was deposited onto the target and air-dried.  
 
Circular dichroism analysis of purified rα-La 
Circular dichroism (CD) spectra were performed on a Jasco J-810 spectropolarimeter 
(JASCO Corporation, Tokyo, Japan) fitted with a Jasco PTC-423S/L Peltier type 
temperature control system. Far-ultraviolet CD spectra were recorded in a 2 mm 
path-length quartz cuvette (Hellma, Mullheim, Baden, Germany) at a protein 
concentration of 0.26 mg/ml. Far-UV CD spectra were analyzed from 190 to 260 nm 
with 1 nm resolution at a scan speed of 50 nm/min and resulted from the average of 
three scans. All measurements were performed in 1 mM Tris (pH 8.5). Temperature 
scans were performed according to a step-scan procedure, where the sample was 
heated from 25°C to 95°C with a heat rate of 2°C/min and cooled back to 25°C at the 
same rate. Every 5°C continuous wavelength spectra were recorded with the 
specified parameters. The final spectra were corrected by subtracting the 
corresponding base line spectrum obtained under identical conditions. Results were 
expressed as the mean residue ellipticity [Θ] at a given wavelength. For the EGTA 
33 
 MANUSCRIPT 1 
experiments 10 mM EGTA was added to the recombinant protein before CD 
analysis.  
The secondary structure content of rα-La was calculated using the secondary 
structure estimation program CDSSTR (32). 
 
Patients and biological materials 
Sera were obtained from cow’s milk allergic patients who had a positive case history 
of cow’s milk allergy, positive skin-prick reactions to cow’s milk and/or specific IgE to 
cow’s milk extract as measured by the ImmunoCAP System (Phadia, Uppsala, 
Sweden). The cow’s milk allergic patient group consisted of persons from Austria 
(n=9), France (n=1), Germany (n=33), Greece (n=2), Italy (n=2), and Spain (n=19). 
Table I shows the available demographic, clinical and serological data for the adults 
(age 22-70 years old) and children (age 1 month-16 years old) with IgE reactivity to 
rα-La. For the anonymous analysis of serum IgE antibodies the permission of the 
Ethical Committee of the Medical University of Vienna was obtained.  
Pasteurized cow’s milk containing 3.5% fat was bought at a local market (NÖM, 
Baden, Austria, batch: 22 550 2:00) and purified natural alpha lactalbumin was 
purchased from Sigma-Aldrich. 
 
IgE reactivity testing and calcium depletion experiments 
For immunoblot analysis 1 µg/gel-slot of rα-La was separated by SDS-PAGE and 
blotted onto nitrocellulose (Schleicher & Schuell, Dassel, Germany) (30, 31). The 
nitrocellulose strips were blocked with PBST (PBS, 0.5% v/v Tween 20) and exposed 
to sera from milk allergic patients diluted 1:20 in PBST over night at 4°C. Bound IgE 
antibodies were detected with 125I-labelled anti-human IgE antibodies (IBL, Hamburg, 
Germany), diluted 1:15 in PBST, and visualized by autoradiography using Kodak 
XOMAT films with intensifying screens (Kodak, Heidelberg, Germany) at -80°C.  
IgE reactivities to micro-arrayed whole cow’s milk extract, rα-La, nα-La, and α-La-
derived peptides were determined as described (33, 19). In brief, milk components 
and for control purposes, HSA, were spotted onto a capillary-flow membrane 
attached to an ordinary microscope glass slide and incubated with 30 µl of patients’ 
sera. rα-La, nα-La, and α-La-derived peptides were spotted in three spot replicates 
after each other in the flow direction with one HSA spot in front of the first spot of 
each component. Cow’s milk extract was spotted later in the flow in six spot 
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replicates across the flow direction with one HSA spot spotted in front of each CM 
spot. Bound IgE antibodies were detected with a fluorophore-conjugated anti-IgE 
antibody at a wavelength of 670 nm. All values were corrected for their proximate 
HSA values. Values exceeding 125 fluorescence intensities (FI), the highest values 
obtained with non-allergic individuals, were considered as positive.  
IgE reactivity to calcium-depleted rα-La was tested by dot-blotting. Aliquots of 1 µg of 
rα-La were dotted onto nitrocellulose membranes (Schleicher & Schuell). The 
nitrocellulose strips were blocked with PBST and exposed to sera from milk allergic 
patients diluted 1:10 or 1:20 in PBST over night at 4°C in the presence of 5 mM 
EGTA (ethylene glycol-bis (ß-aminoethylether)-N, N, N’, N’-tetraacetic acid, Sigma-
Aldrich) or 0.5 mM CaCl2 (calcium chloride dihydrate, MERCK, Darmstadt, 
Germany). Bound IgE antibodies were detected with 125I-labelled anti-human IgE 
antibodies as described for IgE immunoblotting. 
To compare the IgE binding capacity of rα-La with nα-La, 5 µg of nα-La/ml in sodium 
carbonate buffer (pH 9.6) were coated onto ELISA plates (Nunc Maxisorb, Roskilde, 
Denmark) overnight at 4°C. Patients’ sera were diluted 1:10 in Tris-buffered saline 
containing 0.5% v/v Tween 20 (TBST) and were pre-incubated overnight at 4°C with 
10 µg/ml of nα-La or rα-La or for control purposes with TBST (not inhibited, NI). On 
the following day, the plates were washed five times with TBST and blocked with 
TBST for 2.5h at 37°C. The plates were then incubated with the patients’ sera 
overnight at 4°C. Bound IgE antibodies were detected with a monoclonal anti-human 
IgE antibody (BD Biosciences, San Jose, CA) 1:1000 diluted in TBST. After 
incubation overnight at 4°C and five times washing with TBST, bound anti-human IgE 
was detected with 1:1000 diluted HRP-labelled sheep anti-mouse IgG antibodies (GE 
Healthcare, Little Chalfont Buckinghamshire, UK). All determinations were carried out 
in duplicates. 
 
Synthesis of α-La-derived peptides, determination of surface exposed amino acids in 
the peptide sequences 
α-La-derived peptides displayed in Table II and Fig. 1 were synthesized using the 
Fmoc (9 fluorenyl methoxy carbonyl)-strategy with HBTU [(2-/1H-Benzotriazol-1-
yl)1,1,3,3, tetramethyluronium hexafluorophosphat]-activation (0.1 mmol small-scale 
cycles) on an Applied Biosystems peptide synthesizer Model 433A (Foster City, CA) 
and purified as described (34). 
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In order to determine the extent of surface exposure of the amino acid residues in the 
peptides in the complete α-La, the coordinates of the known bovine alpha-
lactalbumin structure were retrieved from the Protein Data Bank (PDB – 1F6S) (35). 
The solvent accessible surface areas were calculated with the program AREAIMOL 
(36, 37) by rolling a probe sphere of 1.4 Å radii over the van der Waals surface of the 
protein. The solvent accessible surface is specified by the centre of the probe 
sphere. In this way the solvent accessible surface of the complete α-La as well as the 
individual residues was determined. 
 
Rat basophil leukaemia (RBL) assays 
For the assessment of the allergenic activity of rα-La and nα-La, RBL cell mediator 
release assays were performed as described previously (19, 38). RBL cells (clone 
RBL-703/21) transfected with the human FcεRI were incubated with sera from cow’s 
milk allergic patients overnight. On the next day the cells were washed, 100 µl of milk 
components (concentration: 0.3 µg/ml) were added and incubated for 1 hour at 37°C, 
7% CO2 and 95% humidity. Aliquots of the supernatants were mixed with assay 
solution (0.1 M citric acid or sodium citrate, pH 4.5 + 160 µM 4-methyl umbelliferyl-N-
acetyl-β-D-glucosamide) and incubated for 1 hour at 37°C, 7% CO2 and 95% 
humidity. Fluorescence was measured with a fluorescence microplate reader 
(Spectrafluor, Tecan, Salzburg, Austria) and specific release was calculated. Values 
obtained with buffer alone were subtracted and values exceeding 5% of mediator 
release were considered as positive.  
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Results 
Expression in E. coli, purification, biochemical, and structural characterization of rα-
La  
We obtained an α-La-cDNA from which an amino acid sequence could be deduced 
that was identical to the α-La protein sequence deposited in the NIH database 
(http://www.ncbi.nlm.nih.gov, accession number: NP_776803). Fig. 1 shows the 
alignment of the deduced α-La amino acid sequence with α-La amino acid 
sequences from different mammalian species. α-La contains an N-terminal leader 
sequence which is cleaved from the mature protein (Fig. 1). A prediction of N-
glycosylation sites revealed the presence of 6 potential N-glycosylation sites in the α-
La sequence (Fig. 1, underlined: 44NNDS, 56NNKI, 57NKIW, 66NPHS, 71NICN, 
102NYWL). The 8 cysteine residues which form disulphide bridges are conserved 
throughout the species and have been boxed (blue) in Fig. 1. Also the domain 
forming the calcium-binding loop, residues 79K-88D, is highly conserved among the 
different species (Fig. 1, yellow box). The amino acids responsible for the binding of 
Ca2+ have been printed in italics. They are identical in all but two sequences. In the 
rat and in the mouse sequence the aspartic acid shows a conservative exchange to a 
glutamic acid. Overall, there were strong similarities between the α-La amino acid 
sequences from cow to man and rodents ranging at approximately 75% identity.  
The α-La cDNA coding for the mature protein and a C-terminal hexahistidine tag was 
expressed in Escherichia coli and approximately 6 mg/l culture of the recombinant 
allergen were purified by nickel affinity chromatography to homogeneity (Fig. 2A).  
Fig. 2A shows the purified protein and the immunoblot in Fig. 2B its reactivity with an 
anti-hexahistidine antibody. MALDI-TOF analysis of purified rα-La resulted in a mass 
peak of 15.1 kDa (Fig. 2C) which corresponds to the molecular weight calculated 
from the sequence, i.e., 15.14 kDa including the methionine and the C-terminal 
hexahistidine tag.  
The far-ultraviolet CD-spectrum of purified rα-La was recorded at 25°C (Fig. 2D, 
black line). It showed minima at 208 nm and 220 nm and a maximum at 193 nm 
which are typical for an α-helical protein. The CD spectrum of the natural α-La 
possessed a more pronounced minimum at 220 nm indicating a better fold of the 
natural protein (data not shown). 
The CD spectrum of rα-La recorded at 95°C was shifted to the left side (i.e., lower 
wave lengths) indicating an increase of denatured protein, however with the protein 
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remaining folded. The CD spectrum recorded after cooling to 25°C was almost 
identical to the spectrum obtained before heating, which suggests that the protein 
has almost completely folded back to its original conformation. In summary, the 
spectra observed during the temperature scan and at 95°C point to a high thermal 
stability of the rα-La. 
It has been observed that calcium-chelating agents such as EGTA can destabilize 
the structure of calcium-binding food allergens (39). However, when we added 10 
mM EGTA to rα-La, the CD spectra at 25°C and 95°C were very similar to those 
recorded without EGTA (data not shown). 
Secondary structure analysis performed with the program CDSSTR using the 
reference database 7 showed that rα-La consists of 8% of α-helices, 32% of β-
sheets, 19% of β-strands and 40% of random coils. The normalized root mean 
standard deviation (NRMSD) value of 0.022 confirmed a good fit between the 
calculated and the experimentally derived spectra.  
 
rα-La is a major cow’s milk allergen according to IgE reactivity 
In first experiments, the specific IgE reactivity of the rα-La was demonstrated by 
immunoblot analysis using serum from a cow’s milk allergic patient. Serum IgE from 
patient A2 reacted specifically with rα-La whereas a control serum from a non-allergic 
individual (NHS) did not contain IgE specific for rα-La (Fig. 3A). 
Next, we tested whether the binding of patients’ IgE is affected by depletion of protein 
bound Ca2+ using EGTA. Depletion of Ca2+ from rα-La led to a reduction of the IgE-
reactivity with sera from two of the three rα-La-reactive patients (Fig. 3B).  
We then investigated whether rα-La contains the IgE epitopes of nα-La by ELISA 
competition analysis. When tested with sera from four α-La allergic patients we found 
that rα-La inhibited the binding to nα-La to the same extent as nα-La (Fig. 3C).  
From most of the cow’s milk allergic patients only small amounts of serum were 
available. We therefore determined the prevalence of IgE recognition for rα-La using 
microarray technology. We found that 57.6% of the cow’s milk allergic patients (n=66) 
who showed IgE reactivity to cow’s milk reacted with the rα-La and 75.8% reacted 
with nα-La. 
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Identification of IgE epitopes of α-La  
In order to identify IgE-reactive epitopes of α-La we synthesized 8 peptides spanning 
the α-La sequence (Fig. 1, Table II). The 8 peptides had a length of 19-20 amino 
acids and overlapped with each other in 5 amino acids. The 8 overlapping peptides 
were also tested by microarray analysis using sera from the 38 patients with IgE 
reactivity to rα-La. We found that 9 patients reacted to Lac1, 18 patients to Lac2, 2 
patients to Lac4, one patient to Lac5, 2 patients to Lac7, and 3 patients to Lac8 (Fig. 
4). In total 22 of the 38 patients with IgE reactivity to rα-La reacted at least with one 
α-La-derived synthetic peptide.  
Interestingly, when we tested also sera from patients without IgE reactivity to 
complete α-La we found 5 patients who reacted with α-La-derived peptides (i.e., 
Lac1, Lac2, Lac4, Lac8).  
Fig. 5A-D show the position of the most frequently recognized peptides Lac1 (red), 
Lac2 (blue), and Lac8 (green) in the ribbon presentation (Fig. 5A, 5C) and in the 
molecular surface presentation (Fig. 5B, 5D). Interestingly, although peptides Lac1 
and Lac2 are part of the N-terminal portion of α-La and peptide Lac8 is located at the 
C-terminal end of α-La, all three peptides appear in close vicinity on the surface of α-
La and seem to define an IgE-reactive patch on the protein. Peptides Lac1 and Lac8 
contain amino acids which are exposed on the surface of α-La and comprise a high 
percentage of the α-La surface (Fig. 5E, F), whereas the other peptides, in particular 
Lac4, contains less surface-exposed amino acids. The surface calculations of the 
peptides (Fig. 5F) show that Lac1 and Lac8 occupy 24.4% and 25.7% of the total α-
La surface, respectively.  
 
rα-La induces specific basophil degranulation  
In order to assess the allergenic activity of the purified rα-La, rat basophil leukaemia 
cells loaded with serum IgE from cow’s milk allergic patients (n=59) were stimulated 
with cow’s milk, rα-La, and nα-La. Of the 59 tested patients, 78% had shown IgE 
reactivity to nα-La and 59.3% exhibited IgE reactivity to rα-La. However, when tested 
for allergenic activity, basophil degranulation was observed for 11.9% with nα-La and 
for 23.7% with rα-La. For those patients whose sera induced basophil degranulation 
with both allergen preparations similar degranulation magnitudes were observed 
ranging from 6.6-45% (median: 12.22%) for nα-La, and 8.5-53.6% (median: 15.62%) 
for rα-La. The allergenic activity of nα-La and rα-La was specific because no 
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degranulation was observed when cells were loaded with sera from non-allergic 
individuals (n=10) (Fig. 6). 
 
Association of cow’s milk-induced symptoms with IgE reactivity and basophil 
degranulation 
Fig. 7 shows the intensities of IgE reactivity and allergenic activity to cow’s milk, rα-
La, and α-La-derived peptides for cow’s milk allergic patients mounting IgE 
responses against rα-La. The patients had been grouped according to the type and 
magnitude of their symptoms. Patients were grouped in those without clinically 
relevant reactions (n=2), with oral allergy syndrome (OAS, n=1), with gastrointestinal 
symptoms (GI, n=3), with gastrointestinal symptoms and other symptoms (urticaria, 
atopic dermatitis, eczema, asthma, rhinoconjunctivitis, n=5), with skin symptoms 
(n=5), with skin and respiratory symptoms (n=5) and those who had severe 
anaphylactic reactions (n=7) upon cow’s milk exposure.  
We found a tendency that rα-La-specific IgE levels were highest in the patients who 
had experienced systemic reactions upon cow’s milk exposure followed by those 
patients with gastrointestinal and other symptoms or with skin and respiratory 
symptoms. IgE reactivities to α-La-derived synthetic peptides were found in each of 
the patients groups except the patients who had only skin and respiratory symptoms 
to cow’s milk.  
The strongest induction of basophil release with rα-La was observed for sera from 
those patients who had experienced systemic reactions to cow’s milk and to a lesser 
degree for those with gastrointestinal and other symptoms whereas almost no 
relevant basophil degranulation was found for patients without reactions or skin 
reactions to cow’s milk (Fig. 7). 
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Discussion 
In this study we isolated a cDNA coding for the cow’s milk allergen α-La and 
characterized the recombinant allergen. Bovine α-La represents a calcium binding 
protein containing one single calcium-binding domain and exhibits high sequence 
homology with α-La from several species including man. The high degree of 
sequence homology of α-La may explain the cross-reactivity of IgE antibodies from 
cow’s milk allergic patients even including the human protein (40, 41). IgE cross-
reactivities have also been reported for caseins from different mammalian species in 
humans allergic to cow’s milk (42). We expressed α-La in Escherichia coli and 
demonstrated that the recombinant allergen represents a folded protein which 
exhibited a remarkable thermal stability. The high stability of the allergen may be 
explained by the presence of protein-bound calcium which is also a feature of other 
calcium-binding allergens, including besides respiratory allergens the major fish 
allergen, parvalbumin (39). α-La as well as fish parvalbumin preserve their allergenic 
activity even after boiling. For α-La it has been shown that the allergen can interact 
with low molecular weight organic compounds including phospholipids which may 
also protect the allergen from digestion (43). Accordingly α-La represents a class I 
food allergen which may sensitize via the gastrointestinal tract (44). The prevalences 
of IgE recognition reported for α-La show considerable variability. Wal et al. (20) 
found IgE reactivity to α-La in 51% of cow’s milk allergic patients (n=92) whereas 
other authors reported recognition frequencies ranging from 6% (Otani, n=17), 
(Docena, n=80), 25% (Host, n=20), 67% (Gjesing, n=21) to 100% (Baldo, n=6) (17, 
18, 21, 26, 27). Goldman et al. described a positive reaction to rα-La in oral challenge 
tests in 53% of cow’s milk allergic patients (n=34) (16). 
We determined the IgE recognition frequency of rα-La and nα-La as well as to α-La-
derived synthetic peptides by microarray analysis using sera from 66 cow’s milk 
allergic patients and found that 57.6% recognized the recombinant protein and 75.8% 
the natural protein. The lower recognition frequency of rα-La versus nα-La may be 
explained by the lack of posttranslational modifications and/or slightly different fold of 
the recombinant protein. However, when rα-La was compared with nα-La regarding 
allergenic activity, we found that the recombinant protein induced more often (i.e., 
23.7%) degranulation of basophils than nα-La (i.e., 11.9%). This result was 
unexpected because nα-La had reacted more frequently with serum IgE than rα-La 
but may be explained by the presence of certain IgE epitopes on nα-La which exhibit 
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low or no allergenic activity as has been reported for example for hapten-like 
structures (45, 46) or carbohydrate epitopes (47, 48). 
We found that patients who had experienced systemic reactions upon cow’s milk 
exposure contained higher rα-La-specific IgE antibody levels compared to those 
patients who had experienced milder symptoms which supports earlier observations 
that patients with more severe symptoms tend to have higher cow’s milk-specific IgE 
levels (49-51). However, it seems impossible to unambiguously identify patients with 
systemic reactions to cow’s milk only on the basis of IgE reactivity. Using the model 
of rat basophil leukemia cells which had been transfected with the human FcεRI for 
testing the allergenic activity of rα-La patients with severe systemic reactions and 
those suffering from gastrointestinal symptoms could be determined. Application of 
rα-La in RBL assays may therefore contribute to the improvement of in vitro 
diagnostic methods for the identification of patients with severe systemic allergic 
reactions to cow’s milk. 
In order to define IgE epitopes of α-La two approaches were pursued. First, we 
studied whether α-La may contain conformational IgE epitopes by depletion of 
protein-bound calcium similar as has been done for other calcium-binding allergens 
(39, 52-56). We could indeed demonstrate that the apo-form (i.e., calcium-depleted 
form) of rα-La showed a reduced IgE binding capacity which may be explained by an 
alteration of the protein conformation due to calcium-depletion (57). The existence of 
conformational epitopes in class I food allergens is quite unexpected but was lately 
described also for other class I food allergens, namely Cyp c 1 (39) Ara h 2 (58), and 
αS1-casein (19). The presence of conformational IgE epitopes on food allergens may 
be explained by sensitization through intact undigested allergen. In this context, it 
has been described by Moreno et al 2005 (43) that α-La interacts with 
phosphatidylcholine and hence becomes protected against digestion (59).  
Besides conformational epitopes we identified sequential epitopes in α-La using 8 
synthetic overlapping peptides spanning the α-La sequence. Interestingly, despite 
different localization within the α-La sequence, two N-terminal, i.e., Lac1 (1E-G19) 
and Lac2 (15L-S34) and a C- terminal peptide, i.e., Lac8 (105L-L123) defined an IgE 
epitope-containing patch on the surface of α-La.  
Our IgE epitope mapping data are in good agreement with other studies. Järvinen 
(22) described four IgE epitopes ranging from amino acid 1E-K16, 13K-W26, 47S-
K58, and 93K-N102 in the native bovine α-La. The study of Maynard, Jost and Wal 
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(60) showed that sequence 17G-K58 and large tryptic peptides sharing this 
sequence were most strongly and frequently recognized. Adams et al (61) showed 
that the synthetic peptide ranging from 5K-A18 contains an IgE-binding epitope. 
Besides the IgE-reactive peptides Lac1, Lac 2, and Lac 8 which formed the major 
IgE-reactive cluster, we found that patients exhibited also IgE reactivity to Lac4 (45N-
D64), Lac5 (60W-K79), and Lac7 (90M-A109).  
A similar clustering of IgE epitopes as described for Lac1, Lac 2, and Lac8 has been 
found for several other respiratory and food allergens such as Bet v 2 (62), Phl p 5 
(63), Phl p 1 (64), Phl p 2 (65), Bos d 5 (66) and may be important for efficient cross-
linking of IgE antibodies on effector cells and hence determine the degree of 
allergenic activity of an allergen.  
The knowledge of IgE epitopes may be of great relevance for the rational design of 
allergy vaccines because it allows constructing hypoallergenic allergen derivatives 
(67) or peptide vaccines (34, 68, 69). Allergy vaccines based on hypoallergenic 
allergen derivatives of respiratory allergens have already been tested in promising 
immunotherapy trials in man and are currently developed also for important food 
allergens (70, 71).  
The recombinant α-La defined by us represents an important cow’s milk allergen 
which can be used for the diagnosis of patients suffering from severe cow’s milk 
allergy. Based on the IgE epitope mapping data it may be possible to develop new 
preventive and therapeutic strategies for cow’s milk allergy.   
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Figure legends 
FIGURE 1. Alignment of α-lactalbumin amino acid sequences from different species. 
The 8 overlapping synthetic peptides (Lac1-Lac8) are boxed. Cysteine residues are 
marked in blue, residues that form the calcium-binding loop are marked in a yellow 
box. Bt, Bos taurus (cow, NP_776803); Bg, Bos grunniens (yak, AAF06793); Bb, 
Bubalus bubalis (water buffalo, ABG78269); Oa, Ovis aries (sheep, CAA29665); Ch, 
Capra hircus (goat, CAA28797); Cf, Canis lupus familiaris (dog, BAA95930); Ss, Sus 
scrofa (pig, AAA31060); Mmul, Macaca mulatta (rhesus monkey, XP_001102116 ); 
Hs, Homo sapiens (man, BAC06860); Rn, Rattus norvegicus (rat, CAA25150); Mmu, 
Mus musculus (mouse, AAA37208); Ec, Equus caballus (horse, LAHO). Dots 
represent identical amino acids, dashes represent gaps. Potential N-glycosylation 
sites are underlined. 
 
FIGURE 2. Expression and purification of rα-La. Coomassie brilliant blue-stained 
SDS-PAGE of a bacterial extract without IPTG-induction (lane 1) and one after IPTG-
induction (lane 2) (A). Urea extraction of rα-La before (lane 3) and after (lane 4) 
purification by Ni-NTA resin affinity columns. Western Blot of rα-La incubated with an 
anti-his tag antibody is shown in B. Molecular masses (kDa) are indicated on the left 
side. C, Mass spectrometric analysis of purified rα-La. The mass/charge ratio is 
shown on the x-axis and the signal intensity is displayed on the y-axis as the 
percentage of the most intensive signal obtained in the investigated mass range. D, 
Structural characterization and thermal unfolding of rα-La. The figure shows the far 
ultraviolet circular dichroism (CD) analysis of purified rα-La in 2 mM Tris (pH 8.5). 
The mean residue ellipticities (Θ, y-axis), recorded at 25°C (continuous line), at 95°C 
(dashed line) and at 25°C after cooling (dotted line) at given wave lengths are shown 
(x-axis). 
 
FIGURE 3. A, IgE reactivity of blotted rα-La with sera from a cow’s milk allergic 
individual (patient A2) and from a non-allergic person (NHS). B, Nitrocellulose-dotted 
rα-La was exposed to sera from three cow’s milk allergic individuals (patient A2, C3, 
C34) and from a non-allergic individual (NHS) in the presence (+) or absence (-) of 
calcium. Bound IgE antibodies were detected with 125I-labelled anti-IgE antibodies 
and visualized by autoradiography. C, IgE reactivity to natural α-La after 
preincubation of sera from four individuals (patients A2, C42, C31, A8) with natural α-
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La (naLa) or recombinant α-La (raLa) or with buffer (no inhibitor, NI). IgE reactivity to 
ELISA plate-bound natural α-La corresponds to optical density values (y-axis). 
 
FIGURE 4. Prevalence (y-axis) of IgE recognition of eight α-La-derived peptides 
tested with sera from 38 rα-La-allergic patients by microarray analysis. 
 
FIGURE 5. Ribbon (A, C) and molecular surface (B, D) presentations of α-La. The N- 
and C-terminus are indicated in A and C. Peptides Lac1, Lac2, and Lac 8 are colored 
in red, blue, and green. E, Contribution of amino acids (1-123) to the molecular 
surface in Ǻ2 and percentages of total surface represented by peptides Lac1-Lac8 
are shown in F. 
 
FIGURE 6. Comparison of basophil degranulation induced by nα-La and rα-La. The 
percentages of mediator release (y-axis) are displayed for allergic patients and non-
allergic controls. The cut off level at 5% is indicated with a horizontal line. 
 
FIGURE 7. Association of cow's milk-induced symptoms with IgE reactivity and 
basophil degranulation. Patients were grouped according to their symptoms related 
to cow’s milk consumption in the following groups: group 1: no reaction, group 2: oral 
allergy syndrome (OAS), group 3: gastrointestinal symptoms only (GI only), group 4: 
gastrointestinal symptoms and other organs affected (GI + others), group 5: skin 
symptoms only (skin only), group 6: skin symptoms and respiratory symptoms (skin + 
respiratory), group 7: severe systemic reactions (systemic reactions). Fluorescence 
intensities (FI) of IgE reactivities to cow’s milk (CM), to recombinant alpha-
lactalbumin (ra-La) and to eight rα-La-derived synthetic peptides (Lac1-Lac8) 
measured by microarray analysis after subtraction of HSA values are indicated in 
different colors. For the mediator release cow’s milk (CM) and rα-La were tested. 
Values higher than 5% of release were considered as positive and are highlighted in 
grey. y, year; mo, month; nd, not done. 
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Table I. Demographic, clinical, and serological characterization of rα-La-positive 
adults (A2-A8, age: 22y-64y) and children (C1-C57, age: 3mo-16y)a 
Patient Age Sex Country Milk-related Other allergies Total IgE CM 
 symptoms (kU/l) (RAST class)
A2 64y f F U,Sys,GI no nd 6
A3 61y f A nk cat,WF,T,K,P 355 4
A5 42y f A OAS mite,cat 148 3
A8 22y f A Sys HE,nuts,pets,PO 3350 6
C1 16y f G NR HE 433 3
C3 13y m I U,E,V,AS PO,HE 909 6
C4 13y m G RC,V HE 866 3
C5 11y f I U, AE, AS candida nd 4
C6 10y f G Ap nd 1432 4
C8 8y m G E,U,AS HE 2200 4
C9 7y m G U,R,AS HE 399 4
C11 6y nk G nk nk 246 3
C17 4y f G Sys nk 974 6
C19 4y m G nk nk 1894 3
C20 4y f G Sys HE 489 5
C21 4y f G nk nk 116 3
C24 3y f G nk nk 125 3
C25 3y m G nk nk 26 3
C27 3y m G Sys nk 325 4
C28 3y f G Sys nk 125 3
C29 3y f G nk nk 201 3
C31 3y nk Gr U, GI beef,fish,Alt 2000 5
C33 2y f S U(face) HE nd 3
C34 2y f S U,AD,V HE,fish nd 5
C35 2y m A AD,OB mite 134 3
C36 2y f G nk nk 83.4 4
C37 2y m G nk nk 193 3
C38 2y m G NR nk 117 3
C40 1y f A AD, OB HE,soja,nuts 217 3
C42 9mo nk Gr U,Sys HE,W 1066 6
C43 9mo f S U,GI no 351 3
C44 7mo m S GI no 32 3
C45 6mo m S U(face), AD no 133 3
C49 3mo f S U nk 1292 3
C50 3mo f S GI no 29 3
C51 3mo m S U,AE no 51 3
C54 3mo f S U(face), AD no 50 3
C57 nk nk G nk nk 1129 5
 
aAbbreviations used in the table: y, year; mo, month; f, female; m, male; F, France; A, Austria; G, 
Germany; Gr, Greece; I, Italy; S, Spain; nk; not known; Symptoms: AD, atopic dermatitis; AE, 
angioedema; Ap, abdominal pain; AS, asthma; E, eczema; GI, gastrointestinal symptoms; NR, no 
reaction; OAS, oral allergy syndrome; OB, obstructive bronchitis; R, redness; RC, rhinoconjunctivitis; 
Sys, systemic reaction; U, urticaria; V, vomiting; Allergen (source): Alt, Alternaria; HE, hen's egg; K, 
kiwi; P, pork; PO, pollen; T, tomato; W, wheat; WF, wheat flour; kU/l, kilo units per liter; CM, cow's 
milk; nd, not done. 
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Table II. Synthetic α-La-derived peptidesa 
Peptide Sequence Length pI MW (Da)
Lac1 EQLTKCEVFRELKDLKGYG 19 aa 6.34 2256.60
Lac2 LKGYGGVSLPEWVCTTFHTS 20 aa 6.74 2182.48
Lac3 TFHTSGYDTQAIVQNNDSTE 20 aa 4.31 2228.27
Lac4 NDSTEYGLFQINNKIWCKDD 20 aa 4.42 2403.60
Lac5 WCKDDQNPHSSNICNISCDK 20 aa 5.3 2307.51
Lac6 ISCDKFLDDDLTDDIMCVKK 20 aa 4.11 2317.67
Lac7 MCVKKILDKVGINYWLAHKA 20 aa 9.52 2330.88
Lac8 LAHKALCSEKLDQWLCEKL 19 aa 6.74 2228.65  
aAbbreviations used in the table: Lac1-Lac8, α-La-derived peptides 1-8; aa, amino acid; pI, isoelectric 
point; MW, molecular weight; Da, Dalton. 
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FIGURE 6 
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      IgE reactivity Mediator release   
Symptoms Patient Age CM  ra-La Lac1 Lac2 Lac3 Lac4 Lac5 Lac6 Lac7 Lac8 CM ra-La   
No reaction C1 16y 5998.5 817.3 -2.3 115.0 -6.0 10.0 -5.0 6.0 0.7 25.0 6.40 -1.00 Microarray (FI) 
  C38 2y 3959.3 406.0 58.3 145.0 92.0 111.3 3.0 7.0 6.3 12.3 5.96 1.09 <125 
OAS A5 42y 270.7 153.0 245.0 83.7 22.0 15.7 1.3 -8.7 -9.3 4.3 3.32 -0.07 125-350 
GI only C6 10y 16071.8 2631.7 76.7 253.7 -135.7 -95.7 -71.7 -94.3 -38.3 63.7 20.15 12.29 350-4850 
  C44 7mo 1849.0 350.3 34.3 14.7 -7.3 19.3 -9.7 11.0 0.0 -16.3 nd nd  >4850 
  C50 3mo 11928.8 1515.7 44.7 44.7 3.7 11.0 6.7 4.7 9.3 14.0 8.83 2.75  
GI + others C3 13y 30760.3 2524.3 -155.0 264.7 -124.7 -111.3 6.7 -3.0 -5.7 2.7 41.51 3.50  
  C4 13y 4326.7 1845.0 40.0 66.7 1.3 31.3 25.0 19.3 10.3 20.0 1.92 1.26 Mediator release 
  C31 3y 48117.3 7277.3 372.0 1655.0 -392.7 -516.3 89.0 93.0 154.7 114.3 32.22 5.12 0-4.9% 
  C34 2y 35437.7 599.7 -267.0 1687.7 1.3 19.3 -6.0 32.7 19.7 111.7 55.70 9.87 ≥5% 
  C43 9mo 2522.8 1244.3 23.0 35.0 -7.7 17.7 -6.3 3.7 2.0 6.7 16.03 13.10  
Skin only C33 2y 628.7 162.3 9.3 12.0 5.7 27.0 8.3 5.3 0.3 -6.3 -2.41 4.59  
  C45 6mo 4345.5 549.0 15.0 26.7 -5.3 5.0 -8.0 2.0 -7.3 0.0 nd nd  
  C49 3mo 7792.3 790.3 79.7 175.7 8.3 45.7 -5.0 27.7 49.0 16.3 1.90 2.24  
  C51 3mo 2129.0 469.7 478.3 383.7 -3.0 36.7 7.7 7.7 5.7 18.0 7.25 0.02  
  C54 3mo 2444.3 181.7 32.3 35.0 -3.7 144.7 2.3 6.0 5.3 15.0 nd nd  
Skin +  C5 11y 24790.3 623.7 -209.7 13.3 -97.7 2.0 55.0 -24.3 -2.0 -6.7 6.97 -0.15  
respiratory C8 8y 13870.3 1838.0 -91.7 75.7 11.0 34.0 32.3 29.3 -3.3 62.7 7.20 0.39  
  C9 7y 14460.3 152.7 41.3 53.7 19.3 57.7 47.7 39.0 38.0 38.0 16.10 -2.01  
  C35 2y 5250.7 977.3 10.7 46.3 5.3 12.3 6.7 3.0 -12.0 0.7 2.11 0.73  
  C40 1y 449.2 170.0 71.7 66.3 3.3 45.3 23.0 22.0 15.3 41.3 4.01 4.28  
Systemic  A2 64y 8535.7 10206.0 2377.7 2263.0 85.3 3834.7 -84.0 16.7 47.3 1080.3 64.00 53.57  
reactions A8 22y 64927.8 16351.7 -233.0 732.3 25.7 -173.0 76.3 10.0 240.7 149.7 13.25 8.47  
  C17 4y 46582.5 9896.7 -409.7 465.0 -97.0 -135.7 206.7 -73.0 -13.7 3.7 36.61 27.56  
  C20 4y 23448.3 2271.3 967.3 175.0 -11.7 19.0 -18.0 14.0 12.3 9.0 8.75 6.71  
  C27 3y 17137.0 2873.3 -8.0 277.0 -5.0 65.0 25.0 34.3 17.0 73.7 36.79 14.59  
  C28 3y 3780.7 125.3 39.7 155.7 -2.3 16.3 5.3 15.0 34.7 15.0 14.05 1.63  
  C42 9mo 42028.0 8449.3 32.0 127.0 -14.7 12.0 -1.3 8.0 2.3 25.7 19.37 16.65  
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ABSTRACT 
Background: Cow’s milk is one of the most common causes of food allergy affecting 
approximately 2.5% of infants in the first years of their life. However, only limited 
information regarding the allergenic activity of individual cow’s milk allergens exists. 
Objective: To analyze the frequency of IgE reactivity and to determine the allergenic 
activity of individual cow’s milk allergens. 
Methods: A nitrocellulose-based microarray based on purified natural and 
recombinant cow’s milk allergens was used to determine IgE reactivity profiles using 
sera from 78 cow’s milk-sensitized individuals of varying ages. The allergenic activity 
of the individual allergens was tested using patients’ sera for loading rat basophil 
leukaemia cells (RBL) expressing the alpha-chain of the human receptor FcεRI.  
Results: Using the microarray and the RBL assay, cow’s milk allergens were 
assessed for frequency of IgE recognition and allergenic activity. Moreover, the RBL 
assay allowed distinguishing individuals without or with mild clinical reactions from 
those with severe systemic or gastrointestinal symptoms as well as persons who 
grew out cow’s milk allergy from those who did not.  
Conclusion: Component-resolved testing using milk allergen microarrays and RBL 
assays seems to provide useful additional diagnostic information and may represent 
a basis for future forms of prophylactic and therapeutic strategies for cow’s milk 
allergy.   
 
Clinical Implications: 
Combined IgE-reactivity testing of recombinant milk allergen components by 
microarray and basophil degranulation may allow identifying patients with severe and 
persistent forms of cow’s milk allergy. 
 
Capsule summary:  
Recombinant cow’s milk allergens may be useful for microarray-based IgE reactivity- 
and basophil degranulation testing to identify patients suffering from severe cow’s 
milk allergy.  
 
Keywords: Cow’s milk allergy, recombinant allergen, microarray, basophil 
degranulation, diagnosis.  
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Abbreviations:
CMA: cow’s milk allergy 
CMP: cow’s milk protein 
GM: goat’s milk 
CM: cow’s milk 
SM: sheep’s milk 
HM: human milk 
MM: mare’s milk 
Lf: lactoferrin 
rLf: recombinant lactoferrin 
BLGA: beta-lactoglobulin variant A 
BLGB: beta-lactoglobulin variant B 
rBLG: recombinant beta-lactoglobulin 
parv: parvalbumin 
BSA: bovine serum albumin 
SSA: sheep serum albumin 
HSA: human serum albumin 
rBSAF1: recombinant BSA fragment 1 
rBSAF2: recombinant BSA fragment 2 
rBSAF3: recombinant BSA fragment 3 
hALA: human alpha-lactalbumin 
ALA: alpha-lactalbumin 
rALA: recombinant alpha-lactalbumin  
GC: goat casein fraction 
CC: cow casein fraction 
SC: sheep casein fraction 
KC: kappa-casein 
rKC: recombinant kappa-casein 
BC: beta-casein 
rBC: recombinant beta-casein 
AC: alpha-casein 
raS1C: recombinant alphaS1-casein 
raS2C: recombinant alphaS2-casein
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INTRODUCTION 
Cow’s milk is one of the most common causes of food allergy in the first years of life 
with around 2.5% of infants showing adverse reactions to cow’s milk.1-3 Symptoms of 
cow’s milk allergy (CMA) range from mild to severe reactions and involve the skin, 
respiratory tract, gastrointestinal tract and in the worst case appear as life-
threatening systemic reactions. The diagnosis of cow’s milk allergy as well as the 
assessment and prediction of the severity of symptoms is particularly difficult for 
infants because only small amounts of serum can be obtained for serological 
diagnosis and it is often impossible to perform provocation tests.4, 5 Due to the 
difficulties of obtaining sufficient serum samples and the lack of highly pure allergens, 
data regarding the prevalence of immunoglobulin E (IgE) recognition of individual 
cow’s milk allergens are incomplete and sometimes controversial.6 Furthermore, 
there is little information regarding the allergenic activities of individual cow’s milk 
allergens. 
Cow’s milk contains more than 25 different proteins of which eight have been 
characterized as allergens. They include alpha-lactalbumin (Bos d 4), beta-
lactoglobulin (Bos d 5), BSA (Bos d 6), and lactoferrin from the whey fraction, 
alphaS1-casein (Bos d 8 alphaS1), alphaS2-casein (Bos d 8 alphaS2), beta-casein 
(Bos d 8 beta), and kappa-casein (Bos d 8 kappa) from the casein fraction (Bos d 8).6 
Here we report the establishment of a miniaturized chip assay which contains highly 
pure recombinant cow’s milk allergens and natural milk allergen preparations for the 
analysis of the IgE reactivity profiles of cow’s milk allergic patients of various age 
groups including infants, children, and adults. The milk allergen array allowed us 
detecting the allergen profiles and frequencies of IgE reactivities towards a panel of 
nine recombinant cow’s milk allergens/allergen fragments with as little as 25 µl of 
serum. In order to assess the allergenic activity of the individual allergen components 
a basophil degranulation test was developed which is based on RBL cells expressing 
the human FcεRI. These cells could be loaded with small volumes of serum and 
allowed us testing the allergenic activity of the individual allergen components. 
 
METHODS 
Clinical description of patients 
Sera from cow’s milk allergic children and adults (Table I) were obtained from Europe 
(Austria: n=12; Germany: n=47; Italy: n=2; Spain: n=16; France: n=1). Patients were 
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selected according to a positive case history, positive skin-prick reactions, and/or 
determination of specific IgE to cow’s milk extract using the ImmunoCAP System 
(Phadia, Uppsala, Sweden). Within the study population three age groups were 
defined (3 month-5 years, n=53; 6-14 years, n=16; 16-70 years, n=9) (Table I). For 
51 patients detailed clinical information regarding milk-related symptoms were 
available (Table I). Results from cow’s milk challenge tests were available of 38 
patients. The analysis of the serum samples was performed after patients were made 
anonymous with approval of the Ethics Committee of the Medical University of 
Vienna. 
 
Natural and recombinant allergens, antibodies 
Purified natural milk proteins (alpha-casein, AC; beta-casein, BC; kappa-casein, KC; 
alpha-lactalbumin, ALA; human alpha-lactalbumin, hALA; beta-lactoglobulin variant 
A, BLGA; beta-lactoglobulin variant B, BLGB; bovine serum albumin, BSA; sheep 
serum albumin, SSA; human serum albumin, HSA; lactoferrin, Lf) and casein 
fractions (goat casein fraction, GC; cow casein fraction, CC; sheep casein fraction, 
SC) were purchased from Sigma-Aldrich (Vienna, Austria). Milk samples from cow 
(CM), sheep (SM), goat (GM), and mare (MM) were bought at a local market and 
stored at -20°C until analysis. Human milk (HM) samples were obtained from a 
lactating woman.7 
cDNAs coding for mature alpha-lactalbumin (rALA), beta-lactoglobulin (rBLG), 
alphaS1-(raS1C), alphaS2- (raS2C), beta- (rBC), and kappa-casein (rKC) and for 
three fragments spanning the whole sequence of bovine serum albumin (rBSAF1: 
amino acids (aa) 1-199, rBSAF2: aa 200-389, rBSAF3: aa 390-590) without N-
terminal signal sequences and with C-terminal hexahistidine tags were obtained from 
a mammary gland cDNA library by IgE immunoscreening or PCR amplification.8 
Recombinant proteins were expressed in the Escherichia coli strain BL21 Codon 
Plus (DE3)-RIPL (Stratagene, La Jolla, CA) and purified using Ni-NTA resin affinity 
columns (QIAGEN, Hilden, Germany). Recombinant parvalbumin (parv) was 
produced as reported.9 
Rabbit anti-sera were raised against each of the purified recombinant milk allergens 
(Charles, River, Kissleg, Germany). The purity of natural cow’s milk allergens was 
tested by ELISA using the rabbit anti-sera raised against the recombinant cow’s milk 
allergens diluted 1:5000 in Tris-buffered saline. Bound IgG antibodies were detected 
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with a 1:1000 diluted HRP-labelled anti-rabbit IgG antibody (GE Healthcare, Little 
Chalfont Buckinghamshire, UK). All determinations were carried out in duplicates and 
are expressed as mean values. 
 
Allergen microarray analysis  
For measurement of IgE reactivity, 0.1-0.15 ng/spot of whole milk extracts, casein 
fractions, and purified as well as recombinant cow’s milk proteins were spotted with a 
Nano-Plotter NP2 (Gesellschaft für Silizium-Mikrosysteme mbH, Großerkmannsdorf, 
Germany) onto a capillary flow membrane that was fixed to an ordinary microscope 
glass slide as described by N ystrand.10 After spotting, the microarrays were pre-
wetted with 30 µl of assay buffer (phosphate buffer, pH 7.5), then incubated with 25 
µl of undiluted sera, washed with 30 µl of assay buffer and assayed with 20 µl of 
detecting antibody. Finally, the microarrays were washed two times with 30 µl of 
assay buffer and bound IgE antibodies were detected with a fluorophore-conjugated 
anti-IgE antibody as fluorescence intensities (FI), measured at a wavelength of 670 
nm (GenePix 4000B Axon Instruments; Molecular Devices, Sunnyvale, CA). The cut 
off level was set to FI = 400 based on values gained with spotted human serum 
albumin that was used as a negative control.  
 
Rat basophil leukaemia (RBL) assays 
The allergenic activity of the milk components was tested using RBL cells expressing 
the human receptor FcεRI. RBL cells were loaded with patients sera and exposed to 
the allergen preparations.8, 11  
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RESULTS 
Establishment and characterization of an allergen chip containing micro-
arrayed milk components  
In total, 27 milk samples (dots 1-9, 11, 12, 14-29) and for control purposes HSA (dots 
13) and the unrelated fish allergen, recombinant parvalbumin (dots 10), were spotted 
in duplicates on a nitrocellulose membrane as shown in the application scheme in Fig 
1, A. Purified IgE (dots 0) was spotted as a position marker. The correct 
immobilization of the allergens on the nitrocellulose chip was checked at a 
wavelength of 635 nm (Fig 1, B). The use of a fluorescence-labelled detection 
antibody allowed determining the fluorescence intensities of the anti-IgE labelling at a 
wavelength of 670 nm. According to the color intensities of the fluorescence signals 
the specific IgE concentrations of the samples could be ranked (i.e., white > red > 
orange>yellow>green>light blue>dark blue) and semi-quantitative results were 
obtained. 
In pilot experiments we compared IgE reactivity profiles by chip analysis and by 
ELISA for certain sera, of which larger volumes were available, and obtained 
comparable results with both tests (data not shown).  
We then tested sera from 78 cow’s milk-sensitized individuals, which we had divided 
into three age groups (Table I), for IgE reactivity using the microarrays. Figure 1, C 
shows representative images of microarray results obtained with sera from three 
cow’s milk allergic patients and with the serum from a non-allergic individual. Serum 
IgE from patient B68, a 13-years-old boy with persistent cow’s milk allergy who 
suffered from urticaria, eczema, vomiting, and asthma after milk consumption, 
reacted with most of the allergens except BSA and lactoferrin. The serum did not 
react with sheep serum albumin, parvalbumin, and HSA (Fig 1, C). Similar results 
were obtained with the serum from patient B63, a 9-years-old girl, who suffered 
mainly from gastrointestinal symptoms and with the serum from patient A18, a 22-
months-old girl, who suffered from urticaria, atopic dermatitis, and vomiting (Fig 1, C). 
Both sera showed IgE reactivity to most of the spotted components. The IgE 
reactivity profiles depicted in Fig 1, C have been obtained with small serum volumes 
of approximately 25 µl. The specificity of the method was demonstrated by the lack of 
IgE-reactivity to the spotted components when serum from a non-allergic person (C) 
was used (Fig 1, C).  
 
85 
 MANUSCRIPT 3 
Frequencies of IgE reactivity to micro-arrayed milk allergens  
A summary of the frequencies of IgE reactivities to micro-arrayed milk allergens is 
shown in Fig 2. In total 78 sera (Table I) were tested for IgE reactivity to micro-
arrayed components. Seventy one of those sera were positive in the cow’s milk 
ImmunoCAP, one serum was negative and six sera were not tested by ImmunoCAP 
measurements. The black bars in Figure 2 show the percentages of IgE reactivities 
for all tested patients. Results from each of the three age groups are also displayed.  
Among the whole milk extracts those from cow (n=66; 84.6%), sheep (n=63; 80.8%), 
and goat (n=53; 67.9%) were most frequently recognized. Mare’s milk and human 
milk were less frequently recognized (30.8% and 17.9%, respectively) (Fig 2, A). The 
casein fractions of cow’s, goat’s, and sheep’s milk reacted with IgE from 
approximately 50% of the tested sera (Fig 2, A).  
Among the natural cow’s milk proteins (Fig 2, B) ALA reacted with 62.8% of the sera 
and thus was the most frequently detected natural cow’s milk allergen followed by 
BLG and AC which were recognized by approximately 50% of the tested sera. BC 
(43.6%) and KC (29.5%) were also frequently recognized, whereas Lf, BSA, and 
SSA showed low IgE binding frequencies (5.1%, 3.8%, 2.6%, Fig 2, B). Interestingly, 
natural human ALA reacted almost with 30% of the sera. In summary, 65 of the sera 
(83.3%) showed IgE reactivity with at least one of the natural cow’s milk allergens.  
Comparing the IgE binding frequencies of natural and recombinant cow’s milk 
allergens some interesting differences were noted (Fig 2, B and C, black bars). While 
the recombinant caseins showed comparable IgE binding frequencies as the natural 
counterparts, rALA and also rBLG reacted with less than half of the sera which had 
reacted with their natural counterparts. Recombinant BSA fragments reacted with a 
similar low percentage of sera as purified natural BSA (Fig 2, B and C). Overall, 49 
(62.8%) sera showed IgE reactivity to at least one of the recombinant allergens.  
A comparison of the IgE recognition frequencies in the different age groups showed 
that the frequencies of recognition were highest in group B (age 6-14 years; Fig 2, 
white bars) followed by group A (age 3 months-5 years; grey bars) and group C (age 
16-70 years; Fig 2, hatched bars). These results reflected the levels of cow’s milk-
specific IgE determined by ImmunoCAP being highest in group B followed by A and 
C (Table I).  
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Natural cow’s milk allergen preparations are contaminated with unrelated milk 
allergens  
In order to analyze whether the discrepancies in the IgE recognition frequencies 
between the recombinant forms of ALA and BLG and their natural counterparts are 
due to contaminations in the natural allergen preparations, we tested the latter with 
specific antibody probes. For this purpose, rabbit antibodies had been raised against 
each of the purified recombinant allergens which showed specific reactivity to the 
protein backbones but did not recognize carbohydrates or other post-translational 
modifications. Each of the antisera reacted with the corresponding natural allergens 
(Table II). However, most of the casein-specific antibodies recognized natural AC, 
BC, and KC preparations which suggests that the natural caseins are not pure (Table 
II). Cross-reactivity between AC, BC, and KC is unlikely because no relevant 
sequence homologies were found when their amino acid sequences were aligned 
(data not shown).  
Natural ALA, BLG, Lf, and BSA preparations did not react with antisera raised 
against other milk allergens and hence appeared to be pure. Yet, the biggest 
discrepancies of IgE reactivity between natural and recombinant components were 
observed in case of ALA and BLG, both representing glycoproteins containing 6 and 
1 glycosylation sites, respectively (data not shown).  
 
Mono- and oligo-sensitization to cow’s milk allergen components in cow’s milk 
allergic patients  
Since impurities were detected in natural casein preparations and since IgE 
reactivities to carbohydrates present in natural allergen preparations should be 
excluded, mono- or oligo-sensitization to cow’s milk allergen components was 
assessed with purified recombinant allergens. It was found that 16 (32.7%) out of the 
49 patients who had reacted with recombinant allergens reacted only with one 
allergen. The other 33 sera (67.3%) reacted with at least 2 allergens (2 allergens: 
n=13; 3 allergens: n=9; 4 allergens: n=1; 5 allergens: n=5; 6 allergens: n=3; 7 
allergens: n=2). There was no obvious difference regarding mono- or oligo-
sensitization in the three age groups.  
In the mono-sensitized group (n=16) six patients exhibited >10 kUa/l cow’s milk-
specific IgE in the ImmunoCAP test. Far more, i.e., 27 patients exhibited >10 kUa/l 
87 
 MANUSCRIPT 3 
cow’s milk-specific IgE in the oligo-sensitized group (n=33) indicating that higher 
cow’s milk-specific IgE levels are due to oligo-sensitization. 
 
Comparison between IgE reactivity and allergenic activity of cow’s milk 
allergens  
In order to determine the biological relevance of IgE reactivity to cow’s milk allergens, 
rat basophil leukaemia (RBL) cells which had been transfected with the α-chain of the 
human Fcε receptor were loaded with sera and challenged with the allergens (Fig 2 
A-C; right panels). Basophil degranulation was observed for 47.4% (n=37) of tested 
patients sera (n=78) with cow’s milk extract, 37.2% (n=29) of the sera showed 
degranulation with at least one natural and 34.6% (n=27) of the sera with at least one 
recombinant allergen. Generally, fewer sera gave positive results in the basophil 
degranulation assay than in the IgE reactivity test. Eighty five percent of sera showed 
IgE reactivity to cow’s milk extract in the microarray but only 47.4% induced basophil 
degranulation (Fig 2, A). The differences between IgE reactivity and basophil 
degranulation were less pronounced for the natural caseins (e.g., AC: IgE reactivity: 
48.7%; basophil degranulation: 25.6%; BC: IgE reactivity: 43.6%; basophil 
degranulation: 34.6%; KC: IgE reactivity: 29.5%; basophil degranulation: 25.6%), 
whereas striking differences were noted for natural ALA and BLG (ALA: IgE 
reactivity: 62.8%; basophil degranulation: 11.5%; BLGA: IgE reactivity: 48.7%; 
basophil degranulation: 28.2%; BLGB: IgE reactivity: 50%; basophil degranulation: 
19.2%) indicating that ALA and BLG have a lower allergenic activity than the caseins.  
When the recombinant proteins were compared regarding their frequency of IgE 
reactivity and allergenic activity, we found for rALA comparable results (rALA: IgE 
reactivity: 24.4%; basophil degranulation: 21.8%) and for rBLG a small difference 
(rBLG: IgE reactivity: 21.8%, basophil degranulation: 12.8%) (Fig 2, C). In contrast, 
recombinant caseins induced much less frequently basophil degranulation than IgE 
reactivities were observed (Fig 2, C).  
Thus the association of IgE reactivity with basophil degranulation was poor. 
However, it was noted that sera from group B with the highest levels of cow’s milk-
specific IgE (Table I) which also contained more IgE positive sera than the other two 
groups induced more frequently basophil degranulation than sera from groups A and 
C (Fig 2, A-C).  
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Identification of patients without and with severe symptoms based on 
microarray and basophil degranulation results 
In the next step we analyzed whether there are any associations between clinical 
symptoms, IgE reactivity and basophil degranulation data (Fig 3). For this purpose, 
patients were grouped in individuals (i) without clinical reaction, (ii) with solely oral 
allergy syndrome, (iii) with only gastrointestinal symptoms, (iv) with gastrointestinal 
symptoms and other symptoms, (v) with only skin symptoms, (vi) with only respiratory 
symptoms, (vii) with skin and respiratory symptoms, and (viii) with severe systemic 
reactions.  
The most striking result was that persons containing IgE antibodies against cow’s 
milk extract and allergens without clinical symptoms showed no relevant basophil 
degranulation with any of the tested components (Fig 3). By contrast, sera from most 
cow’s milk allergic patients who suffered from severe systemic reactions and from 
those who suffered from gastrointestinal symptoms induced basophil degranulation 
with many of the tested components. It appeared that patients with severe systemic 
reactions also showed stronger IgE reactivity to more components than the other 
groups (Fig 3). However, IgE reactivity testing did not allow distinguishing persons 
without symptoms from patients with severe and gastrointestinal symptoms. 
 
IgE reactivity and basophil activation tests with purified cow’s milk allergens 
may identify patients who grew out cow’s milk allergy 
In the course of our study nine of our patients had outgrown cow’s milk allergy and 
for eleven patients it was known that they were still suffering from cow’s milk 
allergy. Figure 4 shows the IgE reactivity profiles and basophil degranulation results 
from these patients. Patients with persistent cow’s milk allergy showed more 
frequent and more intense IgE reactivity to natural as well as recombinant cow’s 
milk allergens than patients who had outgrown their milk allergy. Likewise, patients 
with persistent cow’s milk allergy showed more often and more pronounced 
basophil degranulation than patients who had outgrown milk allergy.  
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DISCUSSION 
In this study we analyzed 78 sera from cow’s milk-sensitized persons from different 
age groups and with different clinical manifestations of cow’s milk allergy for IgE 
reactivity to natural and recombinant milk allergen preparations. The allergens were 
micro-arrayed on a chip to allow testing of small serum volumes. It was therefore 
possible to study the IgE reactivity profiles to several allergen components in infants 
and children. Based on IgE reactivity profiles established with natural cow’s milk 
allergens, ALA > BLG > AC > BC > KC represented the most frequently recognized 
cow’s milk allergens. Recombinant caseins appeared to exhibit similar IgE binding 
properties as the natural caseins and offered the additional advantage of purity. 
“Purified natural caseins” were contaminated with unrelated milk allergens and 
therefore seemed unsuitable for component-resolved diagnosis of cow’s milk allergy. 
A considerable discrepancy in IgE reactivity was noted for ALA and BLG, where the 
recombinant allergens reacted only with approximately half of the sera that reacted 
with the natural allergen. However, only approximately half of the sera which showed 
IgE reactivity to purified natural ALA and BLG showed allergenic activity in the 
basophil degranulation assays, indicating that the natural allergens contain IgE-
reactive structures, such as carbohydrates or other post-translational modifications, 
with low allergenic activity.12 By contrast, approximately the same percentage of sera 
which had reacted with the recombinant ALA and BLG proteins also gave positive 
results in the basophil degranulation assay, indicating that these allergen 
preparations perhaps resemble more closely clinically relevant structures.  
A finding of potential relevance for future allergen-specific therapeutic and 
prophylactic strategies is that the described milk allergen array allowed establishing 
the patients’ sensitization profiles to individual components. Using the microarray we 
identified a considerable percentage of patients who appeared to be mono-sensitized 
towards one major allergen and could discriminate these patients from oligo-
sensitized patients. 
The combination of IgE reactivity testing to micro-arrayed allergens and the testing 
for allergenic activity using RBL cells expressing the human FcεRI turned out to 
provide additional useful diagnostic information. In fact, several studies described 
that basophil activation tests provide additional information for the diagnosis of food 
allergy.13-15 While IgE serology to cow’s milk and cow’s milk allergens was positive for 
many individuals with cow’s milk sensitization but also for individuals without clinical 
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symptoms, the RBL assay may identify the subgroup of individuals without clinical 
symptoms. Also patients with only skin symptoms gave weak or no reaction in the 
basophil degranulation test, whereas all patients with severe systemic and the 
majority of patients with gastrointestinal symptoms induced basophil degranulation. 
Accordingly, a recent study showed that basophil activation tests are capable of 
distinguishing sensitized but clinically tolerant from clinically allergic patients with 
peanut or egg allergy.16 
Moreover, it appeared that the basophil degranulation assay could distinguish 
between cow’s milk allergic patients who outgrow their allergy from those who did not 
because those who grew out milk allergy displayed no basophil activation capacity. In 
this context, a recent study showed that children who are likely to outgrow their cow’s 
milk allergy show reduced basophil activation with heat denatured milk.17  
The gold standard for the diagnosis of clinically relevant cow’s milk sensitization is 
certainly the controlled food challenge test, but it must be kept in mind that this test 
cannot always be easily used, particularly not in small infants and in patients who 
mounted life-threatening reactions upon exposure to cow’s milk.  
The component-resolved microarray test combined with an assessment of the 
allergenic activity of the individual components using a basophil activation assay may 
therefore provide interesting additional diagnostic information. Component-resolved 
diagnosis of cow’s milk allergy may also represent a first step towards the 
development of new immunotherapeutic strategies for cow’s milk allergy similar to 
those which have been developed based on recombinant allergens for respiratory 
allergies.18 
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TABLE I. Characterization of milk-sensitized patientsa 
M
A
N
U
SC
R
IPT 3
Patient Sex Country Milk-related SPT Challenge CMA Other Total IgE Specific IgE to CM
group m/f symptoms CM outgrown allergies (kU/l) (kUA/l)
A: A1-A53 29/22 S (n=15) no reaction (n=2) pos (n=20) posa (n=17) yes (n=9) GP (n=1) 8.36 - 3295 <0.35 - >100
3mo-5y nk (n=2) A (n=8) GI (n=1) neg (n=7) posb (n=6) no (n=6) M,C (n=1) mv: 161 mv: 10.7
(n=53) G (n=30) GI+others (n=5) nd/nk (n=26) nega (n=1) nk (n=38) HE (n=7) (n=49) (n=49)
skin (n=15) negb (n=2) HE+various others (n=6)
resp (n=1) nd/nk (n=27) no (n=11)
skin+resp (n=5) nk (n=27)
sys (n=4)
nk (n=20)
B: B54-B69 10/5 G (n=14) no reaction (n=1) pos (n=9) pos (n=4) no (n=2) HE (n=6) 14.1 - 14525 3.77 - >100
6y-14y nk (n=1) I (n=2) GI+others (n=3) nd (n=7) posb (n=3) nk (n=14) HE+various others (n=1) mv: 866 mv: 18.9
(n=16) skin (n=1) np (n=2) Candida (n=1) (n=15) (n=16)
skin+resp (n=4) nd/nk (n=7) nk (n=8)
sys (n=2)
nk (n=5)
C: C70-C78 3/6 G (n=3) no reaction (n=2) pos (n=4) pos (n=2) no (n=3) HE (n=1) 148 - 3736 1.3 - >100
16y-70y A (n=4) OAS (n=1) neg (n=2) posa (n=1) nk (n=4) M,C (n=1) mv: 433 mv: 5.34
(n=9) F (n=1) resp (n=1) nd (n=3) negb (n=2) na (n=2) PO,AH,M (n=1) (n=7) (n=7)
S (n=1) skin (n=2) nd/nk (n=4) Meat,C (n=1)
sys (n=1) C,WF,T,K,P (n=1)
nk (n=2) GP,dog (n=1)
nk (n=3)
 
94 
aAbbreviations used in the table: y, year; mo, month; f, female; m, male; A, Austria; F, France; G, Germany; I, Italy; S, Spain; CM, cow’s milk; OAS, oral allergy 
syndrome; GI, gastrointestinal symptoms; skin, skin symptoms; resp, respiratory symptoms; sys, systemic reactions; nk, not known; SPT, skin-prick test; pos, 
positive; neg, negative; nd, not done; na, not applicable because patients were asymptomatic; np, not possible; GP, grass pollen; M, mite; C, cat; HE, hen’s egg; 
PO, pollen; AH, animal hair; WF, wheat flour; T, tomato; K, kiwi; P, pork; kU/l, kilo units per liter; kUa/l, kilo units antigen per liter; aopen challenge as described by 
Garcia-Ara C. et al.;19 bdouble-blind placebo-controlled food challenge; mv, median value.  
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TABLE II. Reactivity of natural cow’s milk proteins with specific antibody probesa 
 proteins raS1C raS2C rBC rKC rALA rBLG rLF
AC 1.3 1.3 0.3 0.4 0.0 0.0 0.0
BC 0.4 1.2 1.1 0.8 0.0 0.0 0.0
KC 1.1 1.2 0.1 1.4 0.1 0.4 0.0
ALA 0.0 0.0 0.0 0.0 1.5 0.0 0.0
BLGA 0.0 0.0 0.0 0.0 0.0 1.5 0.0
BLGB 0.0 0.0 0.0 0.0 0.0 1.8 0.0
Lf 0.0 0.0 0.0 0.0 0.0 0.0 0.5
BSA 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Natural
Rabbit antisera
 
aAntibody reactivities are presented as OD values, which are calculated as the OD values obtained 
with the immune sera minus the OD values obtained with the corresponding pre-immune sera. 
Elevated values are given in bold and contaminations are highlighted in grey. 
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FIGURE LEGENDS 
FIG 1. Microarray. (A) Application scheme of micro-arrayed milk components: 0: IgE; 
1: GM; 2: CM; 3: SM; 4: HM; 5: MM; 6: Lf; 7: BLGA; 8: BLGB; 9: rBLG; 10: parv; 11: 
BSA; 12: SSA; 13: HSA; 14: rBSAF1; 15: rBSAF2; 16: rBSAF3; 17: hALA; 18: ALA; 
19: rALA; 20: GC; 21: CC; 22: SC; 23: KC; 24: rKC; 25: BC; 26: rBC; 27: AC; 28: 
raS1C; 29: raS2C. (B) Visualization of protein dots on a microarray slide at a 
wavelength of 635 nm. (C) Detection of IgE-reactive protein spots at a wavelength of 
670 nm after incubation with sera from milk allergic patients (A18, B63, B68) and a 
non-allergic individual (C) and visualization with a fluorescence-labelled anti-IgE 
antibody. 
 
FIG 2. Frequencies of IgE recognition and basophil degranulation. The percentages 
of sera exhibiting IgE reactivity and inducing mediator release are displayed for all 
investigated patients (n=78; black bars) and for the three age groups (Group 1: 3 mo-
5 years; n=53; grey bars; group 2: 6-14 years; n=16; white bars; group 3: 16-70 
years; n=9; hatched bars). (A) Milk samples: CM, GM, SM, HM, MM, CC, GC, SC. 
(B) Purified natural cow’s milk allergens: AC, BC, KC, ALA, BLGA, BLGB, Lf, BSA, 
SSA, HSA, hALA and (C) recombinant allergens/allergen fragments: raS1C, raS2C, 
rBC, rKC, rALA, rBLG, rBSAF1, rBSAF2, rBSAF3, parv. 
 
FIG 3. Associations of milk-related symptoms with IgE reactivities and basophil 
degranulation. Milk-allergic patients were grouped according to milk-related 
symptoms as follows: No reaction; OAS (oral allergy syndrome); GI only 
(gastrointestinal reactions); GI + others (gastrointestinal symptoms and/or skin and/or 
respiratory symptoms); Skin (skin symptoms); Resp (respiratory symptoms); 
Skin+resp (skin symptoms and respiratory symptoms); Severe systemic reactions. 
Displayed items are: Age, RAST class to CM. The intensities of IgE reactivities and 
mediator release to cow’s milk (CM), purified natural cow’s milk allergens (AC, BC, 
KC, ALA, BLGA, BLGB, BSA, Lf), and recombinant cow’s milk allergens (raS1C, 
raS2C, rBC, rKC, rALA, rBLG) are indicated in different colors. 
 
FIG 4. IgE reactivities and inductions of basophil activation in patients with persistent 
and transient cow’s milk allergy. IgE reactivities and basophil degranulation in 
response to cow’s milk (CM), purified natural cow’s milk allergens (AC, BC, KC, ALA, 
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BLGA, BLGB, BSA, Lf), and recombinant cow’s milk allergens (raS1C, raS2C, rBC, 
rKC, rALA, rBLG) are shown for patients with persistent (not outgrown) or transient 
(outgrown) cow’s milk allergy. The intensities of IgE reactivity and basophil activation 
are displayed in different colors. 
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Summary 
 
Background Cow’s milk represents one of the most common causes of food allergy in 
the first years of life. In two thirds of patients adverse symptoms following milk 
ingestion are caused by IgE-mediated allergic reactions whereas for one third the 
mechanisms are unknown.  
Objective The aim of this study was to investigate whether persons suffering from 
non-IgE-mediated cow’s milk intolerance can be distinguished from persons without 
cow’s milk intolerance based on their humoral immune responses to cow’s milk 
antigens. 
Methods We determined IgG1-4 subclass and IgA antibody levels to purified 
recombinant αS1-casein, αS2-casein, β-casein, κ-casein, α-lactalbumin, and β-
lactoglobulin in four groups of clinically defined individuals by ELISA. Group I 
consisted of patients with IgE-mediated cow’s milk allergy (CMA, n=9), group II were 
patients with non-IgE-mediated cow’s milk intolerance (CMI, n=14), group III were 
patients with gastrointestinal symptoms not associated with cow’s milk ingestion (GI, 
n=7), and group IV were control persons without gastrointestinal problems (C, n=26). 
Cow’s milk specific IgE was determined by ImmunoCAP.  
Results Only patients with CMA, but none of the individuals belonging to the other 
groups, had IgE antibodies to cow’s milk. CMA patients mounted the highest IgG1 
and IgG4 antibody levels to αS1-casein, αS2-casein, β-casein, κ-casein, α-
lactalbumin, and β-lactoglobulin. No statistically significant differences regarding 
levels of IgG4, IgA, and complement-binding IgG subclasses (IgG1, IgG2, IgG3) to 
purified cow’s milk allergens were found between CMI patients and persons without 
cow’s milk intolerance (GI and C group).  
Conclusion Cow’s milk intolerant patients cannot be distinguished from persons 
without cow’s milk intolerance on the basis of IgG subclass or IgA reactivity to cow’s 
milk allergens. Antibody-mediated forms of hypersensitivity against cow’s milk 
allergens, besides those mediated by IgE, are unlikely to contribute to cow’s milk 
intolerance. 
 
Key words cow’s milk intolerance, non-IgE-mediated, cow’s milk allergy, IgG 
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Introduction 
 
Cow’s milk is a very common cause of food allergy in the first years of life, affecting 
about 2.5% of infants [1]. IgE-mediated allergy is responsible for approximately 60% 
of cow’s milk-induced adverse reactions. However, for patients without cow’s milk-
specific IgE, the mechanisms are not yet understood [2]. 
Non-IgE-mediated cow’s milk intolerance (CMI) affects infants but is more common in 
adults. These patients do not have circulating cow’s milk protein-specific IgE, they 
also show negative results in skin prick tests and RAST [3-7]. The clinical symptoms 
in CMI patients are normally delayed, starting from one hour to several days after the 
consumption of cow’s milk and affect mainly the gastrointestinal system such as 
nausea, bloating, intestinal discomfort, and diarrhea. Immunological as well as non-
immunological mechanisms may be responsible for non-IgE-mediated reactions to 
cow’s milk proteins [8]. Among the immunological mechanisms basically humoral and 
cellular mechanisms may be considered. Symptoms may be caused by cow’s milk-
specific T cell responses of the Th1 or perhaps Th17 phenotype whereas antibody-
mediated mechanisms may involve Type II or Type III hypersensitivity mechanisms 
such as ADCC or complement activation [8, 9].  
A matter of debate is also the selection of the most reliable method for diagnosis of 
non-IgE-mediated cow’s milk intolerance: either in vitro cellular or antibody-based 
test systems [3, 10-15]. Already studies that tried to investigate IgG and IgA levels to 
cow’s milk allergic as compared to healthy individuals gave controversial results. 
Some studies reported increased levels of milk-specific IgG1 and IgG4 in children with 
atopic dermatitis compared to healthy individuals [16], high IgG1, IgG4, and IgA 
antibodies to α-lactalbumin in atopic children until one year of age and then 
decreasing antibody levels [17]. Other studies showed similar levels of IgA and IgG 
antibodies to cow’s milk proteins in healthy individuals and in patients with CMA [18, 
19] or low cow’s milk-specific IgG levels in CMA patients whether or not tolerance 
was achieved [20]. In studies that also included patients with non-IgE-mediated milk 
hypersensitivities higher IgG4 antibodies to β-lactoglobulin were described for atopic 
children [21] and higher IgG1, IgG4, IgA to α-casein (α-cas), β-casein (β-cas), κ-
casein (κ-cas), α-lactalbumin (α-la), β-lactoglobulin (β-lg) were found in IgE-mediated 
cow’s milk allergic patients as compared to patients with non-IgE-mediated disorders 
and controls [7]. However, the question whether patients suffering from non-IgE-
109 
 MANUSCRIPT 4 
mediated cow’s milk allergy can be distinguished from persons without cow’s milk 
related symptoms based on IgG reactivity to cow’s milk allergens and whether 
antibody-complement-mediated immune mechanisms may play a role has not yet 
been answered.  
In this study we expressed and purified the recombinant cow’s milk allergens αS1-
casein, αS2-casein, β-casein, κ-casein, α-lactalbumin, and β-lactoglobulin. The 
recombinant antigens were used to compare milk allergen-specific IgG1-4 and IgA 
antibody levels in patients suffering from IgE-mediated cow’s milk allergy, in patients 
suffering from non-IgE-mediated cow’s milk intolerance, in patients with 
gastrointestinal symptoms, and in healthy individuals without cow’s milk-related 
symptoms. Our results demonstrate that patients suffering from non-IgE-mediated 
cow’s milk allergy cannot be distinguished from persons without cow’s milk-related 
symptoms based on IgG subclass or IgA reactivity to cow’s milk allergens, which 
contradicts that humoral mechanisms might be involved in non-IgE-mediated cow’s 
milk intolerance.  
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Material and methods 
 
Study groups 
Patients with cow’s milk allergy (CMA, n=9) were diagnosed according to positive 
case history and/or positive provocation test and determination of specific IgE to 
cow’s milk using the ImmunoCAP System (Phadia, Uppsala, Sweden). Patients with 
cow’s milk intolerance (CMI, n=14) had a positive history of reproducible symptoms 
after milk consumption but without any specific IgE to cow’s milk (cut off level 0.35 
kUA/l). Lactose-intolerance was excluded by a negative lactose-intolerance test 
(lactose H2 breath test) in 7 CMI patients (CMI 2, 3, 4, 10, 11, 12, 13). Patients with 
gastrointestinal problems (GI, n=7) had gastrointestinal symptoms not related to 
cow’s milk consumption. Persons without any gastrointestinal problems were 
recruited as controls (C, n=26). They comprised non-allergic as well as patients with 
IgE-mediated allergy to allergen sources other than milk (Table 1).  
Total IgE levels (kU/l) as well as cow’s milk specific IgE levels were measured using 
the ImmunoCAP System (Phadia) for all patients, specific IgE levels to respiratory 
allergens (sx1: timothy grass, rye, birch, mugwort, mite Dermatophagoides 
pteronyssinus, cat dander, dog dander, mould Cladosporium herbarium) and to food 
allergens (fx5: hen’s egg, cow’s milk, codfish, wheat, peanut, soy) were determined 
by ImmunoCAP (Phadia) for cow’s milk intolerant patients and patients with 
gastrointestinal symptoms. 
The study was approved by the Ethics-Committee of the Medical University of Vienna 
and the General Hospital of Vienna. 
 
Biological materials, expression, and purification of recombinant cow’s milk allergens 
Pasteurized cow’s milk containing 3.5% fat was bought at a local market (NÖM, 
Austria, batch: 333 402:51). 
cDNAs coding for αS1-casein (rαS1-cas), αS2-casein (rαS2-cas), β-casein (rβ-cas), 
κ-casein (rκ-cas), α-lactalbumin (rα-la) and β-lactoglobulin (rβ-lg) were either isolated 
by IgE immunoscreening from a cDNA expression library prepared from bovine 
mammary glands or by reverse transcription-PCR from the same tissue [22]. 
Recombinant allergens were expressed in Escherichia coli strain BL 21 Codon Plus 
(DE3)-RIPL (Stratagene, La Jolla, CA) as hexahistidine-tagged proteins and purified 
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using Ni-NTA resin affinity columns according to the manufacturer’s instructions 
(QIAGEN, Hilden, Germany) [22].  
 
ELISA for measurement of IgG1-4 and IgA antibodies specific for purified recombinant 
cow’s milk allergens 
Serum levels of IgG1-4 and IgA to six purified recombinant cow’s milk allergens were 
measured by means of ELISA [26]. In brief, sera were diluted 1:50 for detection of 
allergen-specific IgG1-4 and IgA. Murine mAbs with specificity for IgG1, IgG2, IgG3, 
IgG4, and IgA1/2 (BD Biosciences, San Jose, CA) were used as recommended by the 
manufacturer to detect allergen-specific human immunoglobulins. Murine mAbs were 
traced with a 1:1000 dilution of a horseradish peroxidase-linked sheep anti-mouse 
IgG antibody (GE Healthcare, Little Chalfont Buckinghamshire, UK).  
In order to compare the OD values from different ELISA plates, the results were 
normalized for each immunoglobulin isotype by including a reference serum on each 
ELISA plate. Therefore the first ELISA plate served as a reference plate and the OD 
values from the other ELISA plates were normalized by the ratio between the OD 
value of the reference serum from the reference plate and the OD value of the 
reference serum from the measured plate (mean of duplicate determinations). The 
cut-off level for a positive IgA and IgG measurement was set at 2-fold the OD value 
obtained for the highest buffer control.  
 
IgA and IgG immunoblot analysis 
For immunoblot analysis approximately 40 µg/cm of total cow’s milk proteins were 
separated by SDS-PAGE and blotted onto nitrocellulose (Schleicher & Schuell, 
Dassel, Germany) as described [23, 24]. The nitrocellulose strips were blocked with 
PBST (PBS, 0.5% v/v Tween 20) and then incubated with sera from individuals of the 
four study groups diluted 1:1000 in PBST over night at 4°C. Bound IgA and IgG 
antibodies were detected with an anti-human IgA (clone MH14-1, Sanquin, 
Amsterdam, Holland) and an anti-human IgG antibody (clone MH16-1, Sanquin) 
respectively, which had been 125I-labelled using the ChloramineT method [25] and 
were diluted 1:1000 in PBST. Antibody-binding was visualized by autoradiography 
using Kodak XOMAT films with intensifying screens (Kodak, Heidelberg, Germany).  
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Statistics 
Statistical comparisons were done by analysis of variance. For this, OD values were 
first logarithmized to get homogeneity of variance. In case of statistical significance 
(p<0.05), a post-hoc test (Tukey Hsd) was performed. For all calculations the 
statistical Programm SPSS (2008, version 16.0 SPSS Inc, Chicago, USA) was used.  
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Results 
 
Characterization of the study groups 
Group I consisted of 9 patients with IgE-mediated cow’s milk allergy, 5 children (age 
2 years-16 years; 2 females and 3 males) and 4 adults (age 39 years-69 years; 1 
female and 3 males). These patients suffered from gastrointestinal symptoms, 
respiratory symptoms, atopic dermatitis, and/ or in the worst case systemic reactions 
after consumption of cow’s milk. The diagnosis of IgE-mediated cow’s milk allergy 
was confirmed by the demonstration of cow’s milk allergen-specific IgE in their 
serum.  
Group II consisting of 14 adults (age 24 years-58 years; 8 females and 6 males) with 
a clearly documented intolerance to cow’s milk was designated cow’s milk intolerant 
group (CMI). These patients reported reproducible symptoms after ingestion of cow’s 
milk. Eleven of these patients exhibited gastrointestinal symptoms such as diarrhea, 
abdominal pain, and flatulence after ingestion of milk. Certain patients showed 
angioedema and throat swelling, respiratory symptoms (e.g., cough, rhinitis), atopic 
dermatitis-like symptoms or rhinoconjunctivitis after milk consumption. Five of the 14 
patients suffered also from IgE-mediated allergy to allergen sources other than cow’s 
milk, but none of the 14 patients showed any IgE reactivity to cow’s milk allergens. A 
lactose intolerance test was performed with negative outcome in 7 of the 14 CMI 
patients. One of the patients suffered from celiac disease, another one from irritable 
bowel syndrome and for two patients celiac disease or irritable bowel syndrome was 
suspected. 
A third group of patients with gastrointestinal problems such as diarrhea and 
flatulence not related to cow’s milk consisted of 7 patients (age 19 years-56 years; 4 
females and 3 adults). These patients, designated GI, had no problems when 
consuming cow’s milk, had a negative lactose intolerance test and the presence of a 
chronic inflammatory bowl disease such as ulcerative colitis, Crohn’s disease or 
celiac disease was excluded.  
Group IV, a control group, represented individuals without any gastrointestinal 
symptoms and consisted of 18 persons without any IgE-mediated allergies and 8 
persons with IgE-mediated allergy to allergen sources other than cow’s milk (n=26; 
age 18 years-53 years; 16 females and 10 males). Each of these persons consumed 
regularly cow’s milk without any problems.  
114 
 MANUSCRIPT 4 
Only cow’s milk allergic patients have milk allergen-specific IgE  
Sera from CMA, CMI, GI patients, and controls were analyzed by ImmunoCAP 
regarding their IgE reactivity to cow’s milk (Fig. 1). Only CMA patients but none of the 
individuals belonging to the other groups (CMI, GI, C) showed IgE reactivity to cow’s 
milk. The IgE antibody levels against cow’s milk in the sera from the CMA patients 
ranged from 0.53 to 209.6 kUA/l (Fig. 1).  
 
Cow’s milk allergic patients exhibit elevated IgG1 and IgG4 levels to cow’s milk 
allergens 
Sera from the four groups were tested for IgG1 and IgG4 reactivity to purified 
recombinant cow’s milk allergens including rαS1-casein, rαS2-casein, rβ-casein, rκ-
casein, rα-lactalbumin, and rβ-lactoglobulin by ELISA (Fig. 2). The cow’s milk allergic 
patients showed always the highest IgG1 and IgG4 antibody responses to each of the 
recombinant allergens (Fig. 2 and Table 2). 
After statistical evaluation the following results were considered as statistically 
significant: The IgG1 antibody levels of the CMA patient group were significantly 
higher against rαS1-cas (GI: p<0.01; C: p<0.01) and rβ-cas (GI: p<0.01; C: p=0.03) 
when compared with the GI and C group and against rα-la when compared with the 
GI group (p=0.04). The IgG4 levels were significantly higher against rαS1-cas in the 
CMA group than in the C group (p=0.01) and against rβ-cas (CMI: p=0.02; GI: 
p=0.02; C: p<0.05) compared to the CMI, GI, and C group.  
 
Cow’s milk intolerant patients do not show significantly elevated IgG1 or IgG4 levels to 
cow’s milk allergens compared to persons without cow’s milk-related symptoms  
The median IgG1 and IgG4 antibody levels of the CMI patients were generally very 
low or close to the cut off level (Fig. 2, Table 2). Statistical evaluation showed that 
patients with cow’s milk intolerance did not have significantly higher IgG4 levels 
against the cow’s milk allergens compared to persons without any cow’s milk-related 
symptoms (i.e., GI and C group). Only the IgG1 and IgG4 levels against rαS1-cas 
were slightly elevated compared to GI and C groups, but without reaching any 
significance. 
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Cow’s milk intolerant patients lack significantly elevated levels of cow’s milk allergen-
specific complement-binding IgG subclasses or IgA 
Besides cow’s milk allergen-specific IgG1 and the non-complement-binding IgG4 
subclass we have also analyzed cow’s milk allergen-specific IgG subclasses which 
can activate complement (i.e., IgG2, IgG3) and cow’s milk allergen-specific IgA 
antibody levels (Table 2). Cow’s milk allergen-specific IgG2 and IgG3 antibodies were 
very low in each of the tested groups. Only rκ-casein-specific IgG2 levels were slightly 
elevated in the CMI group but there was no statistically significant difference when 
compared with the GI and the control group (Table 2). Likewise, cow’s milk allergen-
specific IgA levels were low in each of the groups for all tested allergens (Table 2).  
We also investigated the presence of IgG and IgA antibodies specific for cow’s milk 
proteins other than allergens using nitrocellulose-blotted cow’s milk extract (data not 
shown). IgG and IgA reactivity was found mainly against bands migrating at a 
molecular weight of approximately 30 kDa most likely representing the casein 
fraction. No relevant differences regarding IgG and IgA anti-milk reactivity were found 
between the CMI group and the GI and control group (data not shown). 
 
Hierarchy of antigenicity of individual cow’s milk allergens  
If one compares the levels of IgG responses to the individual cow’s milk allergens it 
appears notable that in cow’s milk allergic patients the IgG1 and IgG4 levels to rαS1-
cas were by far the highest. RαS1-cas thus seemed to be far more “antigenic” than 
the other caseins, whereas rα-lactalbumin and rβ-lactoglobulin seemed to be the 
least antigenic milk allergens. Interestingly, the IgG4 levels to β-casein and κ-casein 
were lower than those to α-lactalbumin and β-lactoglobulin in the CMA group. 
Furthermore, we noted that κ-casein was relatively well recognized by IgG1 from the 
CMA, CMI, GI, and control group and by IgG2 antibodies from the CMI and GI group.  
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Discussion 
 
Adverse reactions to food and in particular to cow’s milk represent an important 
health problem. Food intolerance can be caused by immune-mediated as well as by 
non-immune-mediated mechanisms [8]. Among the immune-mediated mechanisms 
for cow’s milk intolerance, IgE-mediated reactions, also commonly termed ‘cow’s milk 
allergy’ represent well defined entities because they are based on the IgE recognition 
of cow’s milk allergens, IgE-mediated effector cell activation and the unambiguous 
diagnosis can be performed by detection of allergen-specific IgE antibodies, 
anamnesis and provocation testing [27]. However, for one third of patients suffering 
from cow’s milk intolerance other mechanisms are operative [28]. For non-
immunological mechanisms it is possible to test for lactose intolerance by breath test 
and/or genetic testing [29, 30]. Regarding immunological mechanisms it is assumed 
that milk-induced gut damage is caused by humoral and/or cellular mechanisms [31].  
Our study demonstrates that patients suffering from non-IgE-mediated cow’s milk 
intolerance cannot be discriminated from persons without milk intolerance on the 
basis of IgG or IgA reactivity to cow’s milk allergens. Previously performed studies 
have provided controversial results and there is currently considerable uncertainty 
regarding the diagnostic value of serological tests measuring IgG antibodies against 
food components for the diagnosis of non-IgE-mediated cow’s milk allergy [3, 7, 10-
21]. We have expressed and purified the major allergens of cow’s milk and used the 
purified proteins to test for IgG1-4 subclass and IgA reactivity in four defined groups of 
patients, comprising patients suffering from IgE-mediated cow’s milk allergy (CMA), 
patients suffering from non-IgE-mediated cow’s milk intolerance (CMI), patients with 
gastrointestinal problems not mediated by cow’s milk (GI) and persons without 
gastrointestinal problems (C). Our results clearly demonstrate that there is no 
significant difference regarding IgG and IgA antibody recognition of cow’s milk 
allergens between the CMI and C group. In fact we have tested for non-complement-
activating IgG4 antibodies as well as for complement-activating IgG subclasses (IgG1, 
IgG2, IgG3) and therefore can exclude with high probability that IgG-mediated 
complement activation and IgG-mediated cellular cytotoxicity may play a significant 
role for milk intolerance in the CMI group.  
When testing for antibody reactivity in cow’s milk allergic patients (CMA) to purified 
recombinant cow’s milk allergens we found that certain allergens were more 
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antigenic than others and αS1-casein appeared as the allergen with the highest 
antigenicity which is in good agreement with results from other studies [7]. In fact the 
majority of earlier studies investigated IgG responses in cow’s milk allergic patients 
and found elevated levels of and IgG1 and IgG4 antibodies [18, 21, 32]. However, 
these studies have not really addressed the question whether IgG and IgA testing is 
a reliable parameter for the identification of patients suffering from non-IgE-mediated 
cow’s milk intolerance (CMI) and whether IgG and IgA testing can distinguish CMI 
patients from persons without cow’s milk intolerance. In addition to testing with 
purified recombinant allergens we have also probed nitrocellulose-blotted cow’s milk 
extracts for antibody reactivity in order to investigate whether proteins other than the 
known cow’s milk allergens may play a role in non-IgE-mediated cow’s milk allergy 
but obtained negative results. We therefore can exclude the possibility that non-IgE-
mediated cow’s milk allergy is due to IgG or IgA recognition of other cow’s milk 
proteins.  
Since our study strongly suggests that humoral immune mechanisms other than 
those mediated by IgE are not of pathophysiological relevance for cow’s milk 
intolerance, future studies may focus on studying the role of cellular immune 
mechanisms for non-IgE-mediated cow’s milk intolerance. It is possible that CMI 
patients contain milk antigen-specific Th1 or perhaps Th17 which either per se or due 
to lack of appropriate control by regulatory T cells and/or Th3 can induce gut 
inflammation. In fact it has been demonstrated that certain CMI patients exhibit 
positive epicutaneous reactions to cow’s milk antigens which would speak for the 
presence of Type IV hypersensitivity reactions at least in a subgroup of patients [2].   
In conclusion, our study contradicts theories stating a role of humoral mechanisms in 
non-IgE-mediated cow’s milk allergy and demonstrates that diagnostic tests based 
on the measurement of cow’s milk antigen-specific IgG and IgA cannot be used to 
diagnose patients suffering from non-IgE-mediated cow’s milk allergy. 
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Figure legends 
 
Fig. 1. Cow’s milk specific IgE levels (kUA/l) in the four study groups as determined 
by ImmunoCAP. IgE levels (y-axis) are displayed for CMA (cow’s milk allergic 
patients, n=9), CMI (cow’s milk-intolerant individuals, n=14), GI (patients with 
gastrointestinal problems, n=7), and C (asymptomatic controls, n=26) as box plots. 
Fifty % of the values are within the boxes and non-outliers are between the bars. 
Upper and lower box plot margins represent the interquartile range, the bar inside the 
boxes indicates the median. The lower limit of detection of the assay is 0.35 kUA/l. 
 
Fig. 2. Cow’s milk allergen-specific IgG1 and IgG4 reactivity in the study groups. IgG1 
and IgG4 antibody levels to rαS1-cas (a), rαS2-cas (b), rβ-cas (c), rκ-cas (d), rα-la (e), 
and rβ-lg (f) were measured by ELISA for the CMA, CMI, GI, and C group and OD 
values corresponding to the antibody levels (y-axes) are displayed as box plots. 
Outliers are not shown. The cut off for a positive reaction is indicated by the 
horizontal line. 
     Table 1. Demographic and clinical features of participantsa 
M
A
N
U
SC
R
IPT 4
Patient Age Sex Milk-related GI Other Other
 symptoms disorders  allergies  allergic Total IgE  CM  fx5 sx1
 symptoms  (kU/l)  (kUA/l)  (kUA/l)  (kUA/l)
CMA 1 13y m AS, E, U, V nk pollen, hen's egg    AS, GI, RC, U 3634 147.4 nd nd
CMA 2 11y f AE, AS, U nk candida AS 114 23.60 nd nd
CMA 3 16y m Sys, AS, U nk fish, nuts, pollen, mite, Alternaria AS, Rh 355 11.6 nd nd
CMA 4 2y m U nk pollen, dog, cat, horse, hen's egg AS, RC 45.6 2.85 nd nd
CMA 5 39y m U (cheese) nk goat's milk, sheep's milk nk 27.2 1.51 nd nd
CMA 6 6y f AD, U, V nk hen's egg, fish AE, U 1037 99.4 nd nd
CMA 7 42y m GI nk cat, dog nk 35.3 0.53 nd nd
CMA 8 64y f Sys, GI, U nk nk nk 1302 209.6 nd nd
CMA 9 69y m GI IBS nk nk 9.79 0.98 nd nd
CMI 1 53y m CO nk mite, cats CO, DY 64.9 <0.35 <0.35 10.3
CMI 2 57y f LS, TS ni rye, oat, wheat RC 47.9 <0.35 <0.35 7.47
CMI 3 50y f GI, RS sus CD birch, shrimp, cockroach nk 81.1 <0.35 <0.35 1.24
CMI 4 39y m GI sus IBS cat, horse nk 26 <0.35 <0.35 2.61
CMI 5 25y f GI nk nk nk 153 <0.35 <0.35 <0.35
CMI 6 29y f GI nk nk nk 10.2 <0.35 <0.35 <0.35
CMI 7 29y m GI nk nk nk 41 <0.35 <0.35 <0.35
CMI 8 48y m RI nk nk nk 14.9 <0.35 <0.35 <0.35
CMI 9 58y f AE, GI, I nk nk nk 8.33 <0.35 0.85 0.95
CMI 10 42y m AD, GI IBS nk nk 16.7 <0.35 <0.35 <0.35
CMI 11 40y m GI, RC ni nk nk 4.87 <0.35 <0.35 <0.35
CMI 12 55y f GI HP-gastritis nk nk 84.6 <0.35 <0.35 <0.35
CMI 13 30y f GI nk nk nk 8.21 <0.35 <0.35 <0.35
CMI 14 24y f AD, GI CD nk nk 13.4 <0.35 <0.35 <0.35
GI 1 56y f no ni nk nk 9.28 <0.35 <0.35 <0.35
GI 2 47y f no food allergy wheat, peanut, soy nk 572 <0.35 pos (W, P, S) nd
GI 3 36y m no sus IBS nk nk 42.6 <0.35 <0.35 2.33
GI 4 33y f no ni nk nk 39.7 <0.35 <0.35 7.67
GI 5 46y f no ni nk nk 6.89 <0.35 <0.35 <0.35
GI 6 30y m no IBS nk nk 131 <0.35 <0.35 23.2
GI 7 19y m no inf. colitis nk nk 49.6 <0.35 <0.35 <0.35
Specific IgE to
Group II: Patients with cow's milk intolerance (CMI, n=14)
Group III: Patients with patients with gastrointestinal symptoms not related to cow's milk (GI, n=7)
Group I: Patients with IgE-mediated cow's milk allergy (CMA, n=9) 
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IPT 4
Patient Age Sex Milk-related GI Other Other
 symptoms disorders  allergies  allergic Total IgE  CM  fx5 sx1
 symptoms  (kU/l)  (kUA/l)  (kUA/l)  (kUA/l)
C 1 50y f no no no no 62.3 <0.35 nd nd
C 2 51y f no no no no 6.16 <0.35 nd nd
C 3 24y f no no no no 70.2 <0.35 nd nd
C 4 25y f no no no no 91.9 <0.35 nd nd
C 5 53y m no no no no 12.3 <0.35 nd nd
C 6 46y f no no no no 8.31 <0.35 nd nd
C 7 21y m no no no no 8.89 <0.35 nd nd
C 8 44y f no no no no 55.1 <0.35 nd nd
C 9 42y m no no no no 27 <0.35 nd nd
C 10 39y m no no no no 11.5 <0.35 nd nd
C 11 27y m no no no no 12.08 <0.35 nd nd
C 12 38y f no no no no 12.2 <0.35 nd nd
C 13 28y f no no no no 7.85 <0.35 nd nd
C 14 30y f no no no no 22.3 <0.35 nd nd
C 15 28y f no no no no 3.69 <0.35 nd nd
C 16 25y f no no no no 5.2 <0.35 nd nd
C 17 37y f no no no no 39.1 <0.35 nd nd
C 18 21y m no no no no 41.4 <0.35 nd nd
C 19 18y m no no mite RC 20.30 <0.35 nd nd
C 20 29y f no no bee I, LR 16.8 <0.35 nd nd
C 21 25y f no no cat, dog, pollen, Aspergillus RC 203 <0.35 nd nd
C 22 31y f no no bee LR 37.4 <0.35 nd nd
C 23 25y m no no mite, wasp, bee LR, RC, U 139 <0.35 nd nd
C 24 25y m no no mite RC 393 <0.35 nd nd
C 25 43y m no no pollen, bee, wasp, cat AS 220 <0.35 nd nd
C 26 30y f no no  dog nk 506 <0.35 nd nd
Specific IgE to
Group IV: Individuals without gastrointestinal problems (C, n=26)
          Non-allergic persons
         Persons with other allergies
 
124 
aAbbreviations: y, years; f, female; m, male; AD, atopic dermatitis; AE, angioedema; AS, asthma; CO, cough; DY, dyspnoea; E, eczema; GI, 
gastrointestinal symptoms; I, itching; LR, local reaction; LS, labial swelling; RC, rhinoconjunctivitis; Rh, rhinitis; RS, respiratory symptoms; Sys, 
systemic reaction; TS, throat swelling; U, urticaria; V, vomiting; CD, celiac disease; HP-gastritis, Helicobacter pylori-gastritis; IBS, irritable bowel 
syndrome; inf. colitis, infectious colitis; ni, not identified; nk, not known; sus, suspected; nd, CM, cow's milk; kU/l, total IgE in kilo units/liter; 
kUA/l, allergen-specific IgE in kilo units antigen/liter; fx5, food allergens: hen’s egg, cow’s milk, codfish, W, wheat, P, peanut, S, soy; sx1, 
respiratory allergens: timothy grass, rye, birch, mugwort, mite Dermatophagoides pteronyssinus, cat dander, dog dander, mould Cladosporium 
herbarium, not done. 
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Table 2. Median OD-levels of IgG1-4 and IgA to purified recombinant cow’s milk 
allergens in the four study groups as determined by ELISA. 
CMA CMI GI C
n=9 n=14 n=7 n=26
rαS1-cas IgG1 2.13 0.17 0.11 0.11
IgG2 0.12 0.06 0.04 0.06
IgG3 0.06 0.05 0.05 0.06
IgG4 1.28 0.15 0.06 0.06
IgA 0.08 0.08 0.07 0.07
rαS2-cas IgG1 0.33 0.16 0.13 0.17
IgG2 0.10 0.06 0.05 0.07
IgG3 0.07 0.06 0.06 0.06
IgG4 0.25 0.05 0.05 0.05
IgA 0.08 0.11 0.08 0.08
rβ-cas IgG1 0.31 0.17 0.10 0.14
IgG2 0.09 0.07 0.06 0.08
IgG3 0.04 0.04 0.04 0.05
IgG4 0.08 0.04 0.04 0.05
IgA 0.09 0.07 0.06 0.07
rκ-cas IgG1 0.29 0.20 0.28 0.20
IgG2 0.06 0.12 0.11 0.09
IgG3 0.05 0.05 0.05 0.05
IgG4 0.09 0.08 0.05 0.06
IgA 0.07 0.09 0.06 0.10
rα-la IgG1 0.25 0.15 0.12 0.14
IgG2 0.08 0.05 0.05 0.06
IgG3 0.06 0.06 0.05 0.07
IgG4 0.28 0.06 0.10 0.06
IgA 0.13 0.10 0.12 0.12
rβ-lg IgG1 0.25 0.11 0.10 0.13
IgG2 0.05 0.04 0.04 0.05
IgG3 0.06 0.06 0.06 0.07
IgG4 0.12 0.12 0.09 0.10
IgA 0.10 0.08 0.08 0.08
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